Abstract: Bee products have long been used in traditional healing practices to treat many types of disorders, including cancer and microbial-related diseases. Indeed, several chemical compounds found in bee products have been demonstrated to display anticancer, antibacterial, antiviral, and antiparasitic properties. With the improvement of research tools and in view of recent advances related to bee products, this review aims to provide broad yet detailed insight into the pharmaceutical prospects of bee products such as honey, propolis, bee pollen, royal jelly, bee bread, beeswax, and bee venom, in the domain of cancer and infectious disease management. Available literature confirms the efficacy of these bee products in the alleviation of cancer progression, inhibition of bacterial and viral proliferation, and mitigation of parasitic-related symptoms. With such potentials, bioactive components isolated from the bee products can be used as an alternative approach in the long-run effort to improve humans’ health at a personal and community level.

Keywords: honeybee products; anticancer; antibacterial; antiviral; antiparasitic
necrosis, apoptosis, and proliferation inhibition in various cancer cells, including liver, breast, lung, prostate, and bladder cancer cells [7].

Honey is one of the most versatile bee products that possesses a wide range of properties and applications. It is prepared by bees from honeydew and nectar [8]. It contains several bioactive components that differ based on the type of bee and environmental conditions under which it was collected [9]. Honey works as an anti-inflammatory, antioxidant, anti-bacterial agent, etc., and improves the adherence of skin grafts and the facilitates the wound healing process [9]. Propolis, also known as bee glue, is collected by bees from shrubs, tree buds, as well as green plants [3]. It is made up of essential oils, resins, pollen, waxes, and numerous organic compounds, such as amino acids, polyphenols, minerals, flavonoids, ethanol, vitamin E, vitamin B complex, and vitamin A. It works against hive-invading bacteria, viruses, and other pathogenic microorganisms [10].

Bee products (Figure 1) are also well-recognized due to their antiviral activities, which can outperform standard drugs in some cases. Clinical data suggested that an ointment containing Canadian propolis outperformed placebo or acyclovir in the treatment of genital herpes simplex [3]. Propolis can also inhibit the replication of hepatitis C virus in vitro, inhibit HIV-1 activity by acting on viral integrase, and propolis containing caffeic acid derivatives is potent against herpes simplex 1 and 2 [11,12]. In addition, honey and propolis have also been reported to yield antiviral activities against some human pathogenic viruses such as influenza virus [13], respiratory syncytial virus (RSV) [14], human herpesviruses [15], influenza virus [16–18], HIV [19], human T-cell leukemialymphoma virus type 1 (HTLV-1) [20], Newcastle disease virus (NDV) [21], RSV [22], poliovirus (PV)-type 1 [23], and dengue virus (DENV) [24]. Other bee products such as bee pollen and bee bread have been shown to be effective as antivirals in an in vitro setting against herpes simplex virus (HSV)-1 and HSV-2 [25] and was moderately active against influenza viruses (strains of H1N1, H3N2, and H5N1) [26]. With their antiviral potentials, bee products such as honey and propolis, have been recently tested in the clinical trials against SARS-CoV-2, an emerging human viral pathogen that has been suggested to cause coronavirus disease (COVID)-19 [27].

Figure 1. Types of bee products.
In addition to their anticancer, antibacterial, and antiviral activities, bee products have been shown to exert antiprotazoal activity against the nematode model *Caenorhabditis elegans* and the intestinal parasite *Giardia lamblia* [3,28,29]. Studies showed that propolis yielded anti-malarial activities against *Plasmodium vivax*, *P. ovale*, *P. malariae*, and *P. falciparum* [28]. Honey and propolis were also used in ancient times for embalming bodies, and honey in traditional medicine was used for treating wounds and pain relief [8]. Royal jelly, another type of bee product, appears to have significant antimicrobial activity, as reported in several studies [27]. Beeswax, a lipid-based complex organic compound secreted by the younger worker bees in liquid form, forms in solidifies and scales when exposed to air [27,30]. In recent years, the crude extract of beeswax has been reported effective against pathogenic bacteria, viruses, and fungi [31]. Bee pollen is obtained from plants and transferred to hive as pollen loads. Load formation includes hydrating pollen with honey or nectar. In winter, pollen stored in honeycomb cells during winter fermentation undergoes lactic fermentation and produces bee bread. The bacteriostatic and bactericidal properties of bee bread and pollen are also well known [3].

Notwithstanding the immense application of bee products in the medical and pharmaceutical sectors [3], bee products also possess a substantial economic value. Bee products are primarily used in the food and cosmetics industries [8]. Honey is a great sweetener [32], and bee pollen is high in protein, fatty acids, and vitamins [33], suggesting their excellent dietary properties. Royal jelly can improve brain function and general wellbeing [34], while bee propolis and bee venom can be tapped as potential sources of anticancer [35,36] and antiviral [37,38] drug candidates. On the other hand, beeswax has antibiotic and skin softening properties; thus, this particular bee product has been extensively used in the cosmetics industry. This review discusses the importance of bee products in the medical-pharmaceutical fields as well as the potential use and prospective implication of bee products against cancer and different types of microbial pathogens and parasites.

2. Types of Bee Products: Description and Components

2.1. Honey

Honey is a natural food substance generated by honeybees from deposits of plant and floral nectar, which are then coalesced with specific substances of honeybee, processed and stored in honeycombs to ripen [39]. The chemical components of honey depend on several factors including the species of honey-collecting bee, its plant source, climatic conditions, geographical region, and storage condition [40]. Honey consists of enzymes (acid phosphatase, amylase, catalase, diastase, glucose oxidase, invertase, and sucrose diastase) and amino acid monomers (alanine, asparagine, glutamine, glycine, and proline) [1]. Various phenolic acid such as caffeic-, cinnamic-, ferulic-, etc. (Figure 2) and several organic acids, mainly as gluconic and citric acid, followed by acetic acid, formic acid, and others in small amounts (Figure 3) are present in honey. These acids are responsible for the acidic pH of honey ranging from pH 3.4 to 6.1 [41]. Flavonoids (Figure 4) such as quercetin, kaempferol, chrysin, apigenin, hesperetin, galangin, catechin, luteolin, myricetin, and naringenin have also been reported in honey. The total phenolic content (TPC) and the total flavonoid content (TFC) of the honey samples varied from 4.2 ± 0.6 to 1.9 ± 0.1 mg QE/100 g and 31.5 ± 2.1 to 126.6 ± 2.7 mg GAE/100 g, respectively [42].

Honey is sweet substance predominantly constituted by monosaccharides like fructose (38%) and glucose (31%) as major sugars, with disaccharides (sucrose, gentiobiose, isomaltose, kojibiose, laminaribiose, maltose, maltulose, nigerose, and trehalose) and trisaccharides (centose, erlose, isomaltosylglucose, isomaltotriose, isopanose, 1-ketose, maltotriose, melezitose, panose, and theanderose) in smaller concentrations (Figure 3) [1,43]. Vitamins and minerals are also reported at very low concentrations, about 0.02%, including all of the water-soluble vitamins, and variable minerals such as P, Na, Ca, K, S, Mg, Cl, Si, Rb, V, Zr, Li, Sr [43,44]. In addition, volatile compounds are detected in honey, such as alcohols, aldehydes, benzene and its derivatives, terpene and its derivatives, ketones, pyran, furan, and acid esters [9,45]. The presence of these chemical composition provides
better understanding of the beneficial effects of honey such as anticancer, antiallergic, antibacterial, antioxidant, antidiabetic, antiparasitic properties, antiulcer, anti-inflammatory, wound healing, and cardioprotective [3,46,47].

Figure 2. Chemical structures of phenolic acids found in bee products.

Figure 3. Chemical structures of organic acids found in honey.
Figure 4. Chemical structures of flavonoids found in bee products.
2.2. Propolis

Propolis or bee glue is a resinous substance that honeybees produce by mixing their salivary gland excretions with exudate accumulated from different parts of plants, mainly branches, bark, flower buds, leaves, and stems. Propolis comes from two Greek words: pro (defense) and polis (city or community) [48]. The color of propolis is varied, ranging from green to brown and reddish. Propolis possesses a sweet or pleasant odor, and becomes soft and sticky upon heating [49]. Typically, raw propolis consists of resins and balms (50–60%), fatty acids and waxes (30–40%), essential oils (5–10%), and other components (5%) such as enzymes (acid phosphatase, adenosine triphosphatase, glucose-6-phosphatase, and succinic dehydrogenase), vitamins (B1, B2, B6, C, and E), minerals (Mg, Cu, F, Ca, K, Na, Mn, and Zn) [50,51]. Propolis must be purified and dewaxed via solvent extraction to remove inert materials and preserve the phenolic fractions for commercialization [52].

Several monosaccharides (fructose and glucose) and a disaccharide (sucrose) are found in propolis. It also contains flavonoids (apigenin, chrysin, acacetin, catechin, daidzein, formononetin, naringenin, kaempferol, luteolin, liquiritigenin, myricetin, pinocembrin, rutin, and quercetin), phenolic acids (caffeic acid, chlorogenic acid, cinnamic acid, gallic acid, 4-hydroxybenzoic acid, 4-hydroxyhydrocinnamic acid, and 4-hydroxybenzoic acid-methyl ester), stilbene derivative (resveratrol), and terpenoids (Figure 6). The TPC and TFC of different samples from different sources such as Brazilian, Chinese, and Australian propolis range from 127–142 mg GAE/g and 33–53 mg QE/g, respectively [53]. Fatty acids such as arachidonic, cis-13,16-docosadienoic, cis-11,14,17-eicosatrienoic, cis-
5,8,11,14,17-eicosapentaenoic, eicosadienoic, elaidic, heneicosylic, linoleic, oleic, palmitic, and palmitoleic acid are also present in propolis [49,54]. Propolis and its extracts confer several biological activities, such as antibacterial, anticancer, antifungal, anti-inflammatory, antimycotic, antioxidant, antiulcer, antiviral, cardioprotective, immunomodulatory, neuroprotective, and wound-healing [35,55,56].

Figure 6. Chemical structures of terpenoids found in propolis.

2.3. Bee Pollen

One of the bee products, namely bee pollen, is produced by worker honeybees as the staple food for developing larvae [57,58]. This product results from the mixture of floral nectar, flower pollen, and enzymes with honeybee salivary substances [58]. The chemical compound of bee pollen depends on plant species, bee activities, and weather conditions [59]. The color of bee pollen is diverse, ranging from bright yellow to black and their shapes are also wide ranging: bell-shaped, cylindrical, thorny, or triangular.
Bee pollen consist of single grains which are sometimes joined with two or more other grains [60]. Bee pollen has a high carbohydrate content (35–61%), especially of monosaccharides (15–24% fructose and 11–18% glucose), disaccharides (4–9% sucrose) and other sugars such as arabinose, erlose, isomaltose, maltose, melibiose, melezitose, raffinose, rhamnose, ribose, trehalose, and turanose account for about 1% [59,61,62]. Moreover, bee pollen contains protein (14–30%), including essential amino acids (10.4%) such as histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, and valine [60,62,63]. Likewise, bee pollen contains lipids at higher amounts about 1–13% after carbohydrates and proteins. Among fatty acids, the most prevalent saturated fatty acids are myristic, palmitic, stearic acids (4.3–71.5%) while the major unsaturated fatty acids are \( \alpha \)-linolenic, linoleic and oleic acids (1.3–53.2%). Arachidonic, behenic, capric, caproic, caprylic, 11-eicosenoic, eicosatrienoic, elaidic, lauric, lignoceric acids also exist in bee pollen [58,64].

Furthermore, bee pollen was reported to contain flavonoids, phenolic acids, and tannins [58]. The total phenolic content (TPC) and total flavonoid content (TFC) of bee pollen of distinct countries are 0.50–213 mg GAE/g and 1.00–5.50 mg QE/g, respectively [33]. The main flavonoids of bee pollen are present in about 1.4% including isorhamnetin, kaempferol, quercetin and its 3-O-glucosides, followed by apigenin, catechin, epicatechin, hesperetin, luteolin, naringenin [60,65]. On the other hand, the glucosides of anthocyanins, delphinidin, malvidin, and petunidin, were identified in bee pollen from Spain [66]. Bee pollen contains the following phenolic acids: caffeic, chlorogenic, ferulic, gallic, \( p \)-coumaric, \( p \)-hydroxybenzoic, rosmarinic, syringic, and vanillic acid [58]. Bee pollen consists of vitamins, both water-soluble 0.6%, such as vitamin B1, B2, B3, B5, B7, B6, B8, B9, C, and vitamin P; and fat soluble 0.1% such as provitamin A (\( \beta \)-carotene), vitamin E and D [67]. Minerals also belong to valuable substances in bee pollen, including macronutrients (Ca, K, Mg, Na, P) and micronutrients (Fe, Cu, Cr, Mn, Se, Si, Zn) [68]. Accordingly, bee pollen was reported as a valuable dietary supplement with therapeutic properties, including antibacterial, antioxidant, anti-atherosclerotic, anticancer, anti-allergic, anti-fungal, chemo-preventive, hepatoprotective, and immunomodulatory activities [69–71].

2.4. Royal Jelly

Royal jelly (bee’s milk) is a viscous whitish to yellow jelly-like substance secreted by the mandibular and hypopharyngeal glands of worker honeybees [72,73]. It is slightly soluble in water with a strong smell and sour or sweet flavor and a pH of 3.1–3.9 [74]. Royal jelly plays an important role in honeybee larvae diet. It is fed exclusively to young larvae of workers and drones in their maturation process, and is provided to queen honeybees during their entire life cycle [75]. Generally, royal jelly contains water (50–70%), carbohydrates (30%), proteins (27–41%), and lipids (3–19%) [48,76]. The major sugars present in royal jelly include fructose and glucose. Moreover, sucrose and other oligosaccharides like erlose, gentobiase, isomaltose, maltose, melezitose, raffinose, and trehalose are present in very small concentrations [76,77]. A unique group of nine soluble major royal jelly proteins (MRJPs 1–9) functions as the specific factors responsible for development of queen honeybees. The peptides of royal jelly including apisimin, jelleines, and royalisin, have been shown to yield antibacterial activity [3].

The lipid composition is reported as fatty acids (80–85%), waxes (5–6%), steroids (3–4%) and phospholipids (0.4–0.8%). Royal jelly fatty acids (Figure 7) are usually either uncommon short chain hydroxy and dicarboxylic acids (8–12 carbon atoms) such as 10-hydroxy-[trans]-2-decenolic acid (10-HDA) and 10-hydroxydecanoic acid (HDAA), [trans]-2-decenolic acid, 24-methylenecholesterol, 4-hydroxyperoxy-2-decenic acid ethyl ester, and sebacic acid, 3-hydroxydecanoic, 9-hydroxy-2-decenic, 8-hydroxyoctanoic, and 9-hydroxydecanoic acid. Among them, 10-HDA and 10-HDAA are specific compounds of royal jelly [78–80].
Royal jelly consists of flavanones (pinobaskin, pinocembrin, hesperidin, naringin, and naringenin), flavones (acetin, apigenin, chrysin, and luteolin), flavonols (fisetin, galangin, isorhamnetin, kaempferol, quercetin, and rutin), phenolic acids (caffeic acid, gallic acid, 4-hydroxy-3-methoxyphenylethanol, 4-hydroxybenzoic acid-methyl ester, 4-hydroxybenzoic acid, 4-hydroxyhydrocinnamic acid, octanoic acids, 2-hexenedioic acid and its esters, dodecanoic acid and its ester, 1,2-benzenedicarboxylic acid, and benzoic acid) and other phenolic compounds such as hydroquinone, methyl salicylate, 2-methoxy-p-cresol, 2-methoxyphenol, and pyrocatechol [48,76]. The TPC and TFC range from 3 to 9 mg GAE/g and 0.1 to 0.5 mg QE/g royal jelly, respectively [74]. In addition, royal jelly contains hormones (prolactin, testosterone, estradiol, and progesterone), minerals (Cu, Fe, K, Mg, and Zn), and vitamins (B-complex, C, D, and E, mainly vitamin P and β-carotene). Vitamin K, also present in bee bread, is not found in fresh bee pollen. Most kinds of bee bread contain 24–34% of carbohydrates. Flavonoids (kaempferol, isorhamnetin, apigenin, chrysin, naringenin, and quercetin) and phenolic acids (p-coumaric, caffeic, ferulic and gallic acids) also show high concentrations [86]. The TPC and TFC of bee bread samples varies from 8.26 ± 0.299 to 43.42 ± 0.779 mg GAE/g and 1.81 ± 0.040 to 4.44 ± 0.125 mg QE/g, respectively [87].

Fatty acids (Figure 8) such as arachidic acid, arachidonic acid, docosahexaenoic acid, eicosapentaenoic acid, linoleic acid, myristic acid, oleic acid, palmitic acid, and α-linolenic acid, (9Z,12Z)-octadeca-9,12-dienoic, (9Z,12Z,15Z)-octadeca-9,12,15-trienoic, (Z)-octadec-9-enoic, (Z)-icos-11-enolic, hexadecanoic and octadecanoic acids were also detected in bee bread [88]. The content of lactic acid in bee bread is higher than 3%. The pH value of bee bread is 4.2, mainly due to the formation of lactic acid [86]. Bee bread was reported to have biological activities including antioxidant, antibacterial, antitumor, antihypertensive, neuroprotective, and antiseptic [52,89–91].

Figure 7. The main fatty acids of royal jelly.
2.6. Beeswax

Beeswax is a liquid substance secreted by the wax glands of younger worker honeybees that is used in the construction of the honeycombs. The color of beeswax turns from white to yellowish-brown after contact with honey and bee pollen. It dissolves completely in chloroform and partially in boiling alcohol [31]. Generally, beeswax consists of more than 300 components, including hydrocarbons (12–16%, Figure 9), mainly heptacosane, nonacosane, hentriacontane, pentacosane and tricosane; free fatty acids (12–14%) such as 15-hydroxypalmitic acid, oleic acid, and palmitic acid; linear wax monoesters and hydroxy monoesters (35–45%), complex wax esters (15–27%) containing 15-hydroxypalmitic acid or diols. Vitamins (A, B1, B4, B6 and P) and minerals (Ca, Cu, Fe, K, Mn, Na, P, and Zn) are also present in beeswax. Beeswax is used in the food, pharmaceutical, and cosmetic industries as an additive [31,52]. In addition, beeswax exhibits antimicrobial activities against *Staphylococcus aureus*, *Salmonella enterica*, *Candida albicans* and *Aspergillus niger* [31].

Figure 8. Chemical structures of fatty acids found in bee products, including bee bread.
Figure 9. Chemical structures of hydrocarbons found in beeswax.

2.7. Bee Venom

Bee venom or apitoxin is a clear liquid secreted by the venom gland of honeybee located in the abdominal cavity. It is injected into victims by a stringer, causing an immunological response, mainly inflammation [3]. Bee venom is soluble in water with a pH 5–5.5. Bee venom is highly hydrophilic due to the fact more than 80% of BV is water. Bee venom constituents include enzymes, predominantly two allergenic peptides: phospholipase A2 and hyaluronidase (Api m2), followed by icarapin, two serine proteases: Api SI and Api SII, and acid phosphatase or Api m3 [92,93]. Minerals such as Ca, Mg, and P are present in measurable concentrations. Volatile compounds are detected in bee venom such as isopentyl acetate, n-butyl acetate, isopentanol, n-hexyl acetate, n-octyl acetate, 2-nonanol, n-decyl acetate, benzyl acetate, benzyl alcohol, and (Z)-11-eicosen-1-ol (Figure 10) [36].

Figure 10. Chemical structures of volatile compounds found in bee venom.

Furthermore, bee venom is composed of a very complex mixture that contains more than 18 active components, including peptides (Figure 11), proteins, enzymes, sugars, amines, phospholipids, pheromones, and volatile compounds [94]. The major amphipathic polycationic peptides, mellitin and apamin, which are a unique component of bee venom. Other peptides such as mast-cell degranulating (MCD) peptide, adolapin, tertiapin, secapin, and cardiopep also present in bee venom [94,95].

Bee venom was investigated as a potential Parkinson’s disease therapy and rheumatoid arthritis, anti-inflammatory, antioxidant, antibacterial, anticancer, antimutagenic, antinociceptive, radioprotective, analgesic, immunomodulatory, anti-apoptotic or anti-secretory activity [7,96,97].
Figure 11. Chemical structures of peptides found in bee venom.
2.8. Drone Brood

Drone brood or apilarnil is a little-known bee product acquired by the collection of drone larvae from drone cells (3–11 days after hatching) [98]. Drone brood is a milky, sweet substance with a slightly acidic taste. The odor of drone brood is similar to that of royal jelly. Drone brood is a tenacious substance of creamy consistency with a yellowish gray color [98].

Drone brood consists of 9–12% protein, including amino acids, mainly 6.5% glutamic acid, 2.1% alanine, 3.6% aspartic acid, 3.6% leucine, 2.9% lysine, 3.4% proline, 2.3% valine, and followed by histidine, methionine, phenylalanine, and tryptophan. Drone brood contains carbohydrate (6–10%), lipid 5–8%, ash 2%, dry matter (approximately 25–35%), hormones (female sex hormones: estradiol, prolactin, progesterone; and male sex hormones: testosterone), vitamins (B1–B6, A, D, and E), and minerals (Mg, Ca, P, Na, Zn, Mn, Fe, Cu, K, and Se). The biological activity of drone brood includes antioxidant, antiatherosclerotic, androgenic and adaptogenic effects [99].

3. Anticancer Properties of Bee Products

There is currently growing interest in bee products particularly in terms of their potential anticancer activities. It has been previously reported that some bee products can interfere with the development of cancer cells. In this review, we highlight several studies regarding the most recent anticancer activities of bee products (summarized in Table 1). In addition, we also discuss the potency of each presented bee product and the possible mechanisms by which the products or their constituents act in inhibiting the cancer cell growth.

As one of the most utilized bee products, honey has been an undoubtedly an important bee product not only because of its nutritional values but also its medicinal properties. In terms of anticancer activities, honey exerts cytotoxicity against several cancer cell lines. For instance, in an MTT assay, honey samples obtained from Morocco decreased the cell viability of human colorectal cancer (HCT-1) cell cultures [100]. Further investigation to identify the constituents in the active honey samples revealed that phenolic compounds such as rosmarinic acid, tannic acid, caffeic acid, coumaric acid, gallic acid, ferulic acid, syringic acid, catechin, and pyrogallol were present [100]. Meanwhile, manuka honey is reported to actively inhibit the proliferation of MCF-7 at various concentrations [101–104]. Acacia honey also exhibited anticancer activity against MCF-7 at a concentration of 5.5% v/v [105]. Beside HCT-1 and MCF-7, honey (0.5 to 1 mg/mL) was also reported to inhibit the growth of PC-3, a prostate cancer cell model [106].

These anticancer activities are suggested to be influenced by the substances that are present in honey and hence, correlate to its mechanisms in inhibiting the growth of cancer cells [107]. In general, honey consists of inverted sugar like glucose and fructose at a relatively high concentration but some compounds such as flavonoids, polyphenols, amino acids, carotenoids, vitamins and minerals may also be found [107,108]. Other phytochemicals such as simple polyphenols and flavonoids (chrysin, apigenin, caffeic acid, chrysin, galangin, kaemferol, pinocembrin, pinobanksin and quercetin) can also be found [109,110]. In the evaluation of the anticancer activity of chestnut honey, a quinoline alkaloid was shown to be responsible for the apoptosis mechanism against castration-resistant prostate cancer (CRPC) cells [111]. Other mechanisms by which honey and its constituents interfere with the development of cancer cells are prevention of cellular damage by free radicals by the antioxidant constituents in honey, induction of apoptosis via cellular signalling pathways and immunomodulation activity, and estrogenic effects [102,107,111,112].

The antiproliferative potencies of propolis have also been studied extensively in recent years. Unlike honey, propolis is not usually tested in a form of a raw product, but rather, it is extracted using methanol, ethanol or other organic solvents before the pharmacological activities are evaluated because of its resinous consistency. Cytotoxic tests against A549 cells, a model of human lung cancer cell, revealed that propolis extract obtained from Turkey indicated inhibition of cell growth [113]. The ethyl acetate fraction of propolis
from Saudi Arabia is reported to inhibit Jurkat cells (a T-lymphocyte leukemia model), as well as human liver carcinoma cells (HEP-62) and squamous carcinoma (SW-756) cell lines [114]. Similarly, propolis from Lebanon was also reported to suppress the growth of Jurkat cells [115]. Interestingly, when tested in other carcinoma cell models such as U251 (glioblastoma) and MDA-MB-231 (breast adenocarcinoma), the hexane fraction is the only fraction to show inhibition against these cell models compared to the aqueous and dichloromethane fraction [115]. These results suggest that less polar substances in the propolis may be responsible for the anticancer activities.

Simple polyphenol compounds such as caffeic acid, chrysin, $p$-coumaric acid, galangin, ferulic acid, and pinocembrin are among the most reported phytochemicals to be found in propolis. These compounds have also been suggested to play significant roles in the suppression of cancer cell growth. Czyewska compared the anticancer activity of extracted propolis to the mixture of polyphenols containing chrysin, galangin and $p$-coumaric acid using CAL-27 cells, a human tongue squamous cancer model. Although the results also showed that the mixture of polyphenolic compounds exhibited higher cytotoxicity than the propolis extract [116], it is important to note that the mixture was tested at higher concentration of polyphenols instead of mimicking the relative concentration each substance found in the tested propolis. One possible mechanism in which propolis may interfere with the development of cancer is by the enhancement of the immune system. As an example, propolis samples from northern Morocco which are reported to be cytotoxic against MCF-7, HCT and THP-1 are shown to enhance production of interleukin-10 (IL-10) and decrease TNF-$\alpha$ and IL-6 production [117], suggesting an immunomodulatory activity of this propolis as a possible mechanism to combat the tested cancer cells. The other mechanisms underlying the anticancer activities of propolis are predicted to be related to its ability to interact with microtubules and induction of tubulin depolymerisation [114], activation of apoptosis via caspase-3, -8 and -9 [116], and reduction of proline in cancer cells via proline dehydrogenase/proline oxidase activity [118].

Bee pollen is another bee product that has been examined for its anticancer properties. Compared to other bee products, bee pollen seems to yield a relatively weaker anticancer potency. In an in vitro assay of anticancer activities using mouse B16 melanoma cells, up to 100 $\mu$g/mL of bee pollen was not able to reduce the cultured cell viability [119]. However, it inhibits intracellular tyrosinase (TYR) and interfere with the expression of mRNA corresponding to TYR and tyrosinase receptor, TRP-1 and TRP-2 [119]. Bee pollens collected from different places in South Korea were tested against human prostate adenocarcinoma (PC-3), human lung carcinoma (NCI-H727), human lung carcinoma (A549), MCF-7, and AGS, resulting in IC$_{50}$ values between 0.9 to >25 mg/mL [120]. Stronger anticancer properties were shown by enzymatically cleaved bee pollen proteins, also known as the hydrolysates. It was reported that the hydrolysate peptides lower than 65 kDa in molecular weight were able to inhibit ChaGo-K1 cells, a human bronchogenic carcinoma model, at an IC$_{50}$ of 1.37 $\mu$g/mL [121]. From the above data, it is known that higher concentrations of bee pollen are required to inhibit certain cancer cell lines. However, it should also be seen as a sign that bee pollen may be less toxic to normal cells although we did not describe its toxicity profiles in this review.

Bee venoms have also been reported to exhibit anticancer properties [122,123]. One of the most notable components in bee venom is melittin, a major protein constituent found in most venoms of bee species under the Apis genus. Melittin from Apis florea and Apis mellifera have been shown to exhibit a relatively strong anticancer activity (IC$_{50}$ = 3.38 and 4.97 $\mu$g/mL, respectively) when challenged against A375 (human malignant melanoma), comparable to that of doxorubicin [124]. A cytotoxicity examination of melittin against HeLa, WiDr and Vero cell lines was also reported, showing anticancer activities with IC$_{50}$ values of 2.54, 2.68 and 3.53 $\mu$g/mL, respectively [125]. Melittin also exerts cytotoxic activity against MDA-MB-231, a human breast cancer cell line, with an IC$_{50}$ of 6.25 $\mu$g/mL [126]. At a concentration of 0.5 $\mu$g/mL, melittin is able to reduce the viability of cultured AGS cells, a gastric cancer model [127]. The anticancer mechanism of melittin is possibly
related to its ability to activate the apoptotic pathway via cytochrome-c discharge and therefore activates caspase-9 which leads to the activation of caspase-3 [124]. In relation to this, further investigation was carried out which indicated that melittin prevents the invasion and migration of melanoma cells in a metastatic cell model, mainly though interference with F-actin reorganization and epidermal growth factor receptor (EGFR) activation [124]. Although it is encouraging that melittin seems to be a promising anticancer agent, there is a growing concern that this protein may also be active against normal cells. Besides, bee venom in general is also highlighted for its adverse cytolytic effects. Therefore, measures to avoid or minimize the disadvantages of bee venom administration in cancer therapy have been attempted. Some of the solutions to this problem are the application of specialized drug delivery systems, i.e., nanoparticles, to carry the toxin protein [128,129], and conjugation of the toxin to specific cancer-targeting biomolecules [7,130,131].

The anticancer potential of other bee products such as royal jelly and bee bread was also reported. Royal jelly’s effect on mammary cancer has been examined using 4T1 cells inoculated in mice. The results revealed that the tumor weight was significantly reduced and further evaluation of the mechanisms revealed changes in interleukin (IL)-2, IL-10 and interferon (INF)-α concentrations in mice plasma [132]. In a recent review regarding the anticancer activity of royal jelly, it was highlighted that the main compound in royal jelly that is thought to be responsible for its anticancer activity is called 10-hydroxydecanoic acid (10-HDA), since it is exclusively found in royal jelly (among the other bee products) at relatively high concentration [133]. However, in another study, it was reported that royal jelly or 10-HDA alone were not effective in inhibiting the growth of human colorectal carcinoma (Caco-2) cells but a mixture of royal jelly and human IFN-α3N at a ratio of 2:1 significantly reduced the cell viability [134]. Miyata et al. expanded the research further to test the anticancer potency of royal jelly in a randomized double-blinded clinical trial. Although the anticancer activity of royal jelly was found to be insignificant, there was a reduction on the adverse events frequencies among patients receiving royal jelly as adjuvant for tyrosine kinase inhibitors [135,136]. In contrast, Osama et al. reported that although a certain potency of royal jelly in protecting the renal functions of patients is observed, it was found to be insignificant in anticancer therapy of cisplatin [137]. Apart from that, the investigation on the mechanisms in the activity of royal jelly as anticancer revealed that it may enhance production of cytokine from mononuclear cells to suppress the growth of U937, a leukemia cell model [138]. Meanwhile, bee bread, a bee product that is closely related to royal jelly, was also shown to have antiproliferative activities against Caco-2 and PC-3 cell lines [139]. Bee bread has also been tested against MCF-7, HeLa, HepG-2 and non-small cell lung cancer (NCI-H460), although the potency was relatively low to moderate (GI50 > 400 to 68 µg/mL) [89]. It consists mainly of polyunsaturated and monounsaturated fatty acids [139], but the substances that are thought to be responsible for the anticancer potency are its flavonoids and polyphenolic constituents including isorhamnetin-O-glycoside, quercetin-O-glycoside, herbacetin glycosides, kaempferol, and myricetin [89].

In general, the anticancer activities of bee products presented in this review reveal that bee products are potential sources of anticancer agents with a wide range of cytotoxic mechanisms. We are aware that anticancer activities of the bee products were mostly assessed using in vitro MTT assays. Hence, a detailed evaluation on these products against cancer-bearing animal models is required to obtain a deeper insight on the influence of different factors on the potencies of these natural products. Additionally, the toxicity profiles of each bee products against normal cells should be evaluated since many anticancer agents are not only toxic to cancer cells but also to normal tissues.
**Table 1. Anticancer potentials of selected bee products.**

| Bee Products          | Identified Substance(s)                                                                 | Tested Cell Lines       | Type(s) of Cancer                        | Possible Mechanism(s)                                                                 | Ref.   |
|-----------------------|----------------------------------------------------------------------------------------|-------------------------|------------------------------------------|-------------------------------------------------------------------------------------|--------|
| Honey                 | Gallic acid, caffeic acid, syringic acid, chlorogenic acid, p-coumaric acid, catechin, quercetin, chrysin | PC-3                    | Human prostate adenocarcinoma            | Not examined                                                                        | [106]  |
| Honey (Tualang)       | Not examined                                                                            | MCF-7, MDA-MB-231       | Breast cancer                            | Modulation of apoptotic signalling pathway by enhancing the expression of p53, p21 and FADD protein | [112]  |
| Honey (Manuka)        | Not examined                                                                            | MCF-7, MDA-MB-231       | Breast cancer                            | Reduction of interleukin (IL)-6 and inhibition of pY-STAT3 signalling. Inhibition of cell invasion and migration | [102]  |
| Honey (Chesnut honey) | 3′-2′-pyrrilonidinyl-kynurenic acid                                                    | CRPC                    | Castration-resistant prostate cancer     | Induction of apoptosis via caspase-3                                                | [111]  |
| Bee pollen            | <65 kDa peptides                                                                        | ChaGo-K-1               | Human bronchogenic carcinoma             | Induction of apoptosis (biomolecular pathway not known yet)                         | [121]  |
| Propolis              | Pinocembrin as the major constituent                                                    | MCF-7, HCT and THP-1    | Breast cancer, human colon cancer, and human leukemia model | Enhanced production of interleukin-10 (IL-10) and decreased production of TNF-a and IL-6 | [117]  |
| Propolis              | Triterpenes, steroids derivatives, and diterpenes                                       | Jurkat HEP-62, SW-796   | T-lymphocyte leukemia, human liver carcinoma, Squamous carcinoma. | Interaction with microtubules; induction of tubulin depolymerisation                  | [114]  |
| Propolis              | Chrysins, galangin and p-coumaric acid                                                  | CAL-27                  | Human tongue squamous carcinoma           | Activation of apoptotic cascades via caspase-3, -8 and -9                           | [116]  |
| Propolis              | Chrysins, caffeic acid, p-coumaric acid and ferulic acid                                | CAL-27                  | Human tongue squamous cancer              | Decreased level of proline in cancer cells via proline dehydrogenase/proline oxidase activity | [118]  |
| Propolis              | 3-O-methylquercetin, chrysin, caffeic acid, CAPE, galangin and pinocembrin              | MCF-7, HCC-27, A549     | Breast cancer, human gastric carcinoma, human lung adenocarcinoma | Induction of apoptosis, promotion of cell cycle arrest via activation of p21         | [140]  |
| Royal jelly           | 10-hydroxy-2-decenoic acid                                                              | MCF-7                   | Breast cancer                            | Not examined                                                                        | [133]  |
| Royal jelly           | Not examined                                                                            | Mouse 4T1               | Mouse mammary carcinoma                  | Increased concentration of IL-2 and interferon (INF)-α; decreased level of IL-10     | [132]  |
| Royal jelly           | 10-hydroxy-2-decenoic acid                                                              | U-937                   | Leukemia                                 | Induce secretion of cytokines by mononuclear cells                                   | [138]  |
| Bee bread             | Polyunsaturated fatty acids (51%) and monounsaturated fatty acids (9.9%)                 | Caco-2 PC-3             | Human colorectal adenocarcinoma, Human prostate adenocarcinoma | Not examined                                                                        | [139]  |
| Bee bread             | Flavonoids and polyphenols                                                              | MCF-7 HeLa              | Breast cancer, Cervical cancer            | Not examined                                                                        | [89]   |
| Bee venom             | Mellitin                                                                                | AGS                     | Gastric cancer                           | Disruption of cell membrane causing necrosis to the affected cells                  | [127]  |
| Bee venom             | Mellitin                                                                                | A375                    | Human lung cancer                        | Induction of apoptosis via activation of caspase-9 and caspase-3, inhibition of invasion and migration of melanoma cells through interference of f-actin reorganisation and epidermal growth factor receptor (EGFR) activity | [124]  |

4. Bee Products as Prospective Sources of Antibacterial and Antiviral Agents

Bacterial and viral infections are two of the top causes of deaths worldwide. An increasing number of reports describing the development of bacterial and viral resistance, including in the form of polymicrobial infections, against currently available antibiotics and antivirals has urged the use of alternative products with potential activities against those
two types of pathogens [141–144]. One of the commodities equipped with such activities are bee products [3,145–149]. Bee products such as honey, propolis, bee pollen, royal jelly, bee bread, and bee venom have been broadly used in the traditional healing practices, including in the management of infectious diseases [49,147,150,151]. A selected list of bee products with antibacterial properties can be seen in Table 2. With their enormous medical and pharmaceutical potentials, bee products shall be considered as one of best prospective sources to discover novel antibacterial and antiviral drugs.

Honey is comprised of more than 150 different substances, including nutrients such as carbohydrates, proteins, vitamins, minerals, water, and different types of polyphenolic compounds [149,150]. Geographical setting and climate condition have been suggested to play a decisive role in determining the composition and concentration of active compounds in the nectar [151], thus the quality and, subsequently, the antimicrobial and antiviral activities of the blossom honey can vary from one to another.

Honey exerts broad spectrum antimicrobial efficacy against different types of pathogenic bacteria [152] and viruses [153]. The antibacterial activities of honey are influenced by numerous physical and chemical properties such as high sugar content (high osmolality), low pH, glucose oxidase activation that leads to hydrogen peroxide production, and in addition to that, the biological action of chemical compounds present in honey such as bacteriocins, bee defensin, methylglyoxal, 3-phenyllactic acid (PLA), and the so-called Major Royal Jelly Proteins (MRJPs) [154]. Honey has been shown to yield exceptional antibacterial activities against both Gram-positive (including methicillin-resistant S. aureus (MRSA)), and Gram-negative bacteria, which are frequently linked to skin infections [155]. Manuka honey, a type of honey derived from Leptospermum scoparium, has been reported to have a strong antibacterial activity against S. aureus, S. epidermidis, Enterobacter aerogenes, Salmonella enterica serovar Typhimurium, Klebsiella pneumoniae, and Escherichia coli [156].

Honey has been reported to yield biological effects not only against bacterial pathogens but also against human pathogenic viruses, including the latest threat of SARS-CoV-2 [157]. Overall reports indicate that honey is a prospective sources of antiviral compounds with excellent in vitro efficacy against varicella zoster virus (VZV) [158] and rubella virus [159]. Honey, either in a single use or in a combination with other products, has also been reported to demonstrate antiviral activity against influenza virus [13], herpes simplex virus (HSV)-1 [160], and respiratory syncytial virus (RSV) [14]. In addition, honey can improve the life of patients infected with human immunodeficiency virus (HIV) by promoting the proliferation of lymphocytes and by maintaining the hematological and biochemical parameters at optimal conditions [160,161].

The antibacterial activity of other types of bee products such as propolis, bee pollen, royal jelly, bee bread, and bee venom have also been reported [3,145,148,162]. Propolis exerts its antibacterial potential using two distinct mechanisms: either by promoting the activation of host immune responses (indirect action) or via direct interaction of its component(s) with certain parts of bacteria, for example by disruption of cell wall synthesis and alteration of membrane potential [148,163]. Research carried out by a Brazilian group demonstrated the antibacterial activity of propolis against MRSA [164], most likely due to the presence of artepillin C. Separate studies by Japanese and Chilean groups confirmed the effectiveness of propolis against Porphyromonas gingivalis [165] and Streptococcus mutans [166], respectively, suggesting the potential use of propolis in the management of periodontal diseases. In addition, the high content of kaempferide, artepillin C, drupanin and p-coumaric acid present in the ethanolic extract of propolis has been shown to positively correlate with its excellent antioxidant and antimicrobial activity against diverse types of pathogenic bacteria, including S. aureus, S. saprophyticus, Listeria monocytogenes, and E. faecalis [167]. In addition to its antibacterial effect, propolis has also been reported to exert antiviral activity against many human pathogenic viruses, including human herpesviruses [15], influenza virus [16–18], HIV [19], human T-cell leukemia-lymphoma virus type 1 (HTLV-1) [20], Newcastle disease virus (NDV) [21], RSV [22], poliovirus (PV)-type 1 [23], and dengue virus (DENV) [24]. Recently, flavonoids of propolis and honey such as
rutin, naringin, and quercetin, have been suggested as candidates for potential adjuvant treatment against SARS-CoV-2 [168].

Bee-collected pollen, simply called bee pollen, and bee bread are two bee products commonly known for their dietary value [145]. Based on the published literature, bee pollen and bee bread demonstrate good antimicrobial activities against several human bacterial and viral pathogens [145]. However, like honey and propolis, the antimicrobial activities of bee pollen and bee bread are varied, and largely dependent on the geographical source of the collected samples and the solvents used in the extraction process [145]. Chilean bee pollen extracts inhibited the growth of *Streptococcus pyogenes* I.S.P. 364-00 but did not show any biological activities against *S. aureus* ATCC 25923, *P. aeruginosa* ATCC 27853, and *E. coli* ATCC 25922 [169]. Interestingly, Slovakian bee pollen extract demonstrated good antibacterial features against a clinical isolate of *E. coli* CCM 3988 [170]. Nonetheless, a general observation in several studies is that the antibacterial action of bee pollen is much higher towards Gram-positive bacteria than their Gram-negative counterparts [169,171–173] with some exceptions [174,175]. It is important to note, however, that almost all the antibacterial data were generated in vitro, so it is urgent to confirm the antibacterial efficacy of bee products using currently available vertebrate [176–179] or invertebrate [180–185] in vivo model systems.

In addition to their antibacterial efficacies, bee pollen and bee bread have been reported to display antiviral activities. For example, bee pollen of date palm was found to be active against HSV-1 and HSV-2 [25] and bee pollen extracts of Korean *Papaver rhoeas* was fairly effective against influenza viruses (strains of H1N1, H3N2, and H5N1) [26]. The antiviral activity of bee pollen was most likely due to the action of flavonoids such as luteolin, galangin, kaempferol, and quercetin. Luteolin has been shown as one of the most potent inhibitors of the neuraminidase of influenza virus [26], thus is a prospective anti-influenza drug candidate (as a class of neuraminidase inhibitor). In addition, quercetin was shown to interact with the HA2 subunit of hemagglutinin and inhibit the entry of influenza virus into the host cells [186]. Quercetin-mediated inhibition of hemagglutinin might play a determinant role in the prevention of the hemagglutinin-sialic acid interaction that is required in influenza virus entry. With an increasing rate of viral resistance against the available anti-influenza drugs, such a mechanism shall play a future role in the pharmacological treatment of influenza virus infections.

The emergence of SARS-CoV-2, the causative agent of coronavirus disease (COVID)-19, in late 2019 has increased researchers’ interest in the medical and pharmaceutical potentials of bee products. Several published literatures have encouraged the use of bee products such as honey, propolis, bee pollen, bee bread, and even bee venom, in the management of COVID-19. Lima et al., for example, argued that apitherapy is one of alternative ways that can be tapped to prevent and/or to manage some of the COVID-19-associated symptoms [27]. Indeed, honey and other bee products contain a number of compounds that have been shown effective as antivirals, thus potentially promising against SARS-CoV-2 [27,157,187]. On the basis of such argument, several randomized clinical trials are now carried out to investigate whether the use of honey and propolis in the management COVID-19 are truly effective [27].
Table 2. Antibacterial activity of selected bee products.

| Bee Products | Country | Bacteria | Assay Method | Results | Ref. |
|--------------|---------|----------|--------------|---------|------|
| Leptospermum honey (80 different honeys derived from *Leptospermum* species) | Australia | *Staphylococcus aureus* (ATCC 29923) | In vitro (phenol equivalence assay) | Majority of Australian *Leptospermum* honey tested in the experiments demonstrated non-peroxide antibacterial activity (NPA) and to a greater extent correlates to their high content of methylglyoxal (MGO) and dihydroxyacetone (DHA) | [188] |
| 21 types of honey of different botanical source, derived from the Olympus mountain | Greece | Clinical isolates of methicillin-resistant *S. aureus* (strain 1552) and carbapenem-resistant *P. aeruginosa* (strain 1773) | In vitro (agar well diffusion assay and microtiter plate assay) | All honey samples yielded antibacterial activity against both tested bacteria. Some honey samples were active in a manner dependent on the presence of hydrogen peroxide and proteinaceous compounds | [189] |
| Sesamum indicum honey (seven types of sesame honey obtained from different location in West Bengal) | India | *Salmonella enterica* serovar Typhi, *S. enterica* serovar Typhimurium, *Escherichia coli* and *Vibrio cholerae* | In vitro (disc diffusion assay and microbroth dilution assay) | The antibacterial activity of sesame honey against the tested enteropathogens was good, with the best recorded activity was against both *Salmonella* species | [190] |
| New Zealand’s Manuka Honey (UMF +20, UMF +16, New Zealand, +10), Sidr honey, and *Nigella* Saudi Arabia sativa honey | New Zealand, Cuba, and Kenya | *Methicillin* sensitive- (ATCC 29213 and 10 strains of MSSA clinical isolates) and *methicillin* resistant *S. aureus* (ATCC 26112 and 10 strains of MRSA clinical isolates) | In vitro (disc diffusion assay and microbroth dilution assay) | Manuka honey demonstrated bactericidal activity against both MSSA and MRSA while Sidr and *Nigella sativa* honey yielded only bacteriostatic effect at tested concentrations | [191] |
| *Melipona beecheii* honey (Cuba); Manuka honey (New Zealand), *Apis mellifera* honey (Cuba), and African *A. mellifera* honey (Kenya) | New Zealand, Cuba, and Kenya | 51 clinical isolates (34 Gram-positive, 17 Gram-negative) | In vitro (microtiter plate assay for antibiofilm activity) | All honey tested in the study demonstrated good antibacterial and antibiofilm activity with Cuban *M. beecheii* honey had the highest activity in both | [192] |
| Ten samples of honey of different origins (polyfloral, linden, acacia, manna, and sunflower) | Romania | *S. aureus*, *Staphylococcus epidermidis*, *S. enterica* serovar Typhimurium, *Bacillus cereus*, *B. subtilis*, *Pseudomonas aeruginosa*, *E. coli*, and *Listeria monocytogenes* | In vitro (disc diffusion assay) | All honey samples demonstrated good antibacterial activity against all tested pathogens with *S. aureus* and *P. aeruginosa* were the most sensitive ones. It seems that the origins and the color of honey, but not acidity, play a role in the antibacterial activity of honey | [193] |
| *Apis mellifera* ligustica propolis (extracted using methanol) | Australia | *S. aureus* (ATCC 25923) and *Klebsiella pneumoniae* (ATCC 13883) | In vitro (agar diffusion and broth dilution assays) | The examined Australian propolis demonstrated antibacterial effect against *S. aureus* (bactericidal) but did not yield any effect on the *K. pneumoniae* | [194] |
| Brazilian brown and green propolis (extracted either using ethanol, hexane, or dicholomotane) | Brazil | *S. aureus* (ATCC 6538), *B. subtilis* (ATCC 6633) and *Micrococcus luteus* (ATCC 10240) | In vitro (micro-diffusion assay) | Of all samples examined in the study, the dichloromethane extract of both brown propolis and green propolis yielded the highest antibacterial effect against the tested pathogens | [195] |
| Propolis of *T. fiebrigii* bees (extracted using ethanol) | Brazil | *S. aureus* (ATCC 43300), *S. aureus* (ESA 654), *S. epidermidis* (ATCC 12228), *S. epidermidis* (ESA 675), *Enterococcus faecalis* (ATCC 43300), *E. faecalis* (ESA 553), *K. pneumonia* (ATCC 4352), *K. pneumoniae* (ESA 154), *P. aeruginosa* (ATCC 15442), *P. aeruginosa* (ESA 22), *Proteus mirabilis* (ATCC 43300) and *P. mirabilis* (ESA 37) | In vitro (micro-dilution assay) | The Brazilian propolis demonstrated antibacterial effect against all tested microorganisms but mainly active against Gram-positive bacteria | [196] |
| Bee Products | Country | Bacteria | Assay Method | Results | Ref. |
|--------------|---------|----------|--------------|---------|------|
| Red propolis of Africanized *Apis mellifera* | Brazil | Standard strains of *E. coli* (ATCC 25922) and *S. aureus* ATCC 6538 and the clinical isolates of *E. coli* 06 (EC06), *P. aeruginosa* 03 (PA03), *P. aeruginosa* 24 (PA24) and *S. aureus* 10 (SA10) | In vitro (micro-dilution assay) | The Brazilian red propolis demonstrated antibacterial activity against all tested pathogens, including the clinical isolate ones. The range of MIC values was dependent on the pathogen species (128–512 µg/mL for *E. coli* strains), (64 µg/mL to >1024 µg/mL for *S. aureus* strains), and (512 µg/mL for *P. aeruginosa* strains) | [197] |
| Red propolis, green propolis, and brown propolis (traditionally extracted using ethanol or supercritical extraction method) | Brazil | *S. aureus* (ATCC 25923) and *Enterococcus* sp. (ATCC 29712), *Klebsiella* sp. (ATCC 1706/700665), and *E. coli* (ATCC 25922) | In vitro (micro-dilution assay) | Of all samples, Brazilian red propolis extract yielded the highest antibacterial activity. Green propolis extract demonstrated weak to moderate antibacterial activity for most samples and brown propolis extract did not yield any antibacterial effect against the tested strains. None of the examined samples was active against *E. coli* | [198] |
| 19 propolis samples (collected from six different regions and extracted using methanol) | Chile | Methicillin-sensitive *S. aureus* (ATCC 25923), methicillin-resistant *S. aureus* (ATCC 43300), *E. coli* (ATCC 25922), and the clinical isolates of *Pseudomonas* spp., *E. coli*, *P. mirabilis*, *Salmonella* enteritidis, *Salmonella* sp., and *Yersinia enterocolitica* | In vitro (micro-dilution assay) | The antibacterial effect of propolis obtained from central valley was better than the ones collected from the Andreas slopes or the coastal areas. The samples’ MICs were ranging from 31.5 to >1000 µg/mL and the ones with MIC ≤ 62.5 µg/mL demonstrated good antibacterial effect against *Pseudomonas* sp., *E. coli*, *S. enteritidis*, and *Y. enterocolitica* | [199] |
| Propolis collected from different geographical regions (extracted using either ethanol or water) | Germany, Irlandia, Czech Republic | *S. aureus*, *Staphylococcus saprophyticus*, *S. epidermidis*, *S. pneumoniae*, *Streptococcus pyogenes*, *Streptococcus agalactia*, *Streptococcus thermophiles*, *B. subtilis*, *Enterococcus casseliflavus*, *K. pneumonia*, *Klebsiella oxytoca*, *E. coli*, *O157:H7*, *P. aeruginosa*, *Salmonella choleraesuis*, *Shigella flexneri*, *Haemophilus influenzae*, *Acinetobacter baumannii*, *Burkholderia cepacia*, *Y. enterocolitica*, *Enterobacter cloacae*, one strain of MRSA, and one strain of Vancomycin-resistant enterococci (VRE) | In vitro (micro-dilution assay) | Both ethanol and water propolis extracts demonstrated good antimicrobial activity against most of Gram-positive bacteria (range of MICs: 0.08–5 mg/mL), with the Irish propolis yielded the highest bactericidal effect followed by Czech and German. All propolis extracts demonstrated moderate antibacterial activity against MRSA and VRE and also against β-lactamase positive *H. influenzae*, and *S. pneumoniae*. Propolis ethanol extract, but not water extract, yielded moderate antibacterial activity against Gram-negative pathogens tested in the study (MICs: 0.6–5 mg/mL) | [200] |
| Propolis and bud poplar resins (extracted using ethanol) | Italy | *P. aeruginosa* PAO1 (ATCC 15692) and transgenic *P. aeruginosa* (P1242) with the luciferase gene and luciferin substrate (under the control of a constitutive P1 integron promoter) | In vitro (micro-dilution assay) | Both ethanol extracts (propolis and bud poplar resins) demonstrated good antibacterial activity against *P. aeruginosa* biofilm and negatively affected the swimming and swarming motility properties of *P. aeruginosa* | [201] |
| 24 propolis samples (collected from different geographical location in Morocco; hydro-alcoholic extracts) | Morocco | *S. aureus* (ATCC 6538) and three clinical isolates of MRSA (MRS02, MRS05, and MRS06) | In vitro (disk diffusion method) | Propolis extract (MIC 0.36 mg/mL) was able to attenuate the virulence of *S. aureus* ATCC 6538 and the MRSa strains. The impairment of biofilm formation was also observed | [202] |
| Propolis of *Populus alba*, *P. nigra*, *P. tremula*, *Acer pseudoplatanus*, *Betula verrucosa*, *Pinus silvestris*, and *Aesculus hippocastanum* (extracted using methanol or dichloromethane) | | *S. aureus* (ATCC 25923), *S. epidermidis* (ATCC 12228), *P. aeruginosa* (ATCC 27853), *E. coli* (ATCC 25922), *K. cloacae* (ATCC 13047), and *K. pneumoniae* (ATCC 13883) | In vitro (disk diffusion method) | The dichloromethane extract of propolis demonstrated good antibacterial activity against all tested pathogens (MICs: 0.90–1.34 mg/mL) | [203] |
### Table 2. Cont.

| Bee Products | Country | Bacteria | Assay Method | Results | Ref. |
|--------------|---------|----------|--------------|---------|------|
| Green propolis (extracted using ethanol, methanol, diethyl ether or water) | Taiwan | *S. aureus* (BCRC 10780, BCRC 10781 and BCRC 10451), MRSA (ATCC 43300), *B. subtilis* (BCRC 10255), *L. monocytogenes* (BCRC 14845), *P. aeruginosa* (BCRC 10944), and *E. coli* (BCRC 10675) | In vitro (micro-dilution assay) | Taiwanese green propolis extracts demonstrated good antibacterial activity against MRSA and all propolins, particularly propolin C, yielded good efficacy against *S. aureus, B. subtilis,* and *L. monocytogenes* | [204] |
| 29 bee pollen samples (collected during the dry seasons of 2016, 2017, and 2018; extracted using ethanol) | Chile | *S. aureus* (ATCC 25923), *P. aeruginosa* (ATCC 27853), *E. coli* (ATCC 25922), and *S. pyogenes* (I.S.P. 364-00) | In vitro (diffusion method and broth dilution method) | All bee pollen extracts (collected in three different years) demonstrated good antibacterial activity against *S. aureus,* but did not yield antibacterial effect on *S. aureus, P. aeruginosa,* and *E. coli* | [169] |
| Three Greek bee pollen (collected from from *Cistus creticus* L. (rock rose) at three different locations; extracted using ethanol, butanol, dichloromethane, or cyclohexane) | Greece | *S. aureus* (ATCC 25923), *S. epidermidis* (ATCC 12228), *P. aeruginosa* (ATCC 227853), *E. coli* (ATCC 25922), *E. cloacae* (ATCC 13047), and *K. pneumoniae* (ATCC 13883) | In vitro (micro-dilution assay) | The butanol extract demonstrated good antibacterial activity against all pathogens tested in the study, probably due to the high content of flavonoids, such as quercetin and kaempferol glucosides. No antimicrobial activity was seen in both cyclohexane and dichlorometane extracts | [205] |
| Bee bread and propolis of Stingless bee (*Heterotrigona itama* species; extracted using ethanol or hexane) | Malaysia | *S. aureus,* *B. subtilis,* *E. coli,* and *Salmonella* | In vitro (diffusion method and broth dilution method) | All bee bread and propolis extracts demonstrated good antimicrobial activity against all tested bacteria (MIC: 6.67–33.33 µL/mL), with higher preference to Gram-positive (*S. aureus* and *B. cereus*) than Gram-negative bacteria (*E. coli* and *Salmonella*). Ethanol extracts yielded stronger antibacterial activity than their hexanic counterparts | [206] |
| *Castanea sativa* Mill. pollen grains (collected at Erfelek (4 sites) and Ayancık (5 sites) Turkey district of Sinop; extracted using methanol) | | *S. aureus* (ATCC 6538), MRSA, *E. faecalis* (ATCC 51299), *M. luteus,* *Bacillus cereus* (7064), Vancomycin-resistant *Enterococcus* (VRE), *E. coli* (ATCC 11293), and *K. pneumoniae* | In vitro (disk diffusion method) | Bee pollen extracts yielded higher antibacterial activity against Gram-positive bacteria than their Gram-negative counterparts | [207] |
| Royal jelly sample | Singapore | *Fusobacterium nucleatum,* *Aggregatibacter actinomycetemcomitans,* *Porphyromonas gingivalis,* and *Prevotella intermedia* | In vitro (micro-dilution assay) | Royal jelly demonstrated good antibacterial activity against periodontopathic bacteria tested in the study | [208] |
| Royal jelly sample (Yamada Bee Farm, Okayama, Japan) | Japan | *P. aeruginosa* (PA01) wild-type strain and four clinical isolates | In vitro (micro-dilution assay) | Royal jelly did not yield antipseudomonal activity at concentration of less than 25%. However, at concentration of less than 25% of the antibiotic was observed on both the abiotic surface and the epithelial cell model | [209] |
| Bee bread sample (hydromethanolic extract) | Morocco | *S. aureus* (ATCC 6538), *B. cereus* (food isolate), *L. monocytogenes* (NCTC 7973), *E. coli* (ATCC 35210), *E. cloacae* (human isolate), *S. Typhimurium* (ATCC 13311) | In vitro (micro-dilution assay) | Hydromethanolic extract of bee bread demonstrated antibacterial activity against all tested pathogens (MIC: 0.04–0.175 mg/mL, MBC: 0.08–0.35 mg/mL) | [210] |
| Bee bread (five different regions of Ukraine; extracted using ethanol) | Ukraine | *S. aureus* (CCM 4223), *E. coli* (CCM 3988), *S. enterica subs. enterica* (CCM 3807), and *Bacillus thuringiensis* (CCM 19) | In vitro (disk diffusion method) | All bee bread samples yielded good antibacterial activity against antibiotic-resistant Gram-positive and Gram-negative bacteria tested in the study. The antibacterial strength of bee bread samples on certain bacteria was varied, mainly depends on the geographical location of sample collection | [211] |
Table 2. Cont.

| Bee Products                        | Country       | Bacteria                                                                 | Assay Method                                                                                   | Results                                                                                       | Ref.   |
|-------------------------------------|---------------|--------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|--------|
| Apis mellifera venom (compared to mellitin) | n/a           | Borrelia burgdorferi strain B31 (ATCC 35210)                             | SYBR Green I/Propidium iodide assay and biofilm assay                                            | Both bee venom and mellitin demonstrated good antimicrobial activity against the free form of B. burgdorferi and the biofilm-associated form | [162]  |
|                                    | Brazil        | S. aureus (ATCC 13565, ATCC 14558, ATCC 19095, and ATCC 23235, all Enterotoxigenic), and five clinical isolates of MRSA (recovered from human specimens) | The resazurin microtiter assay (REMA)                                                          | Apitoxin and melittin yielded antibacterial activity against MRSA (MIC: 7.2 µg/mL, and 6.7 µg/mL, respectively). Apitoxin and mellitin had no effect on the production of enterotoxin and/or its release. | [212]  |
| Apis mellifera venom (commercial, freeze-dried) | n/a           | Pseudomonas putida (ATCC 700008), Pseudomonas fluorescens (NCIMB 9046) and E. coli K-12, MG1655 (ATCC 47076), | In vitro viability assay and biochemical analysis                                              | Bee venom exerted its antibacterial activities against the tested pathogens via alteration in the membrane permeability, destruction of bacterial cell wall, cell contents leakage, and inactivation of bacterial metabolic activity leading to cell death | [213]  |
| Apis mellifera venom (apitoxin)     | Ecuador       | Salmonella (CECT 4395) and L. monocytogenes (CECT 934) and 49 S. enterica and 7 L. monocytogenes strains isolated from poultry products | In vitro (micro-dilution assay)                                                               | Apitoxin is effective against foodborne pathogens tested in the study (MIC range: 16–32 µg/mL for L. monocytogenes and 256–1024 µg/mL for S. enterica) | [214]  |

5. Antiparasitic Potential of Bee Products

Parasitic diseases are still among the most challenging public health issues in the countries with subtropical, tropical, and temperate climates [215–217]. One factor contributing to the spread of these infections is the lack of an effective and safe therapy. The current pharmacotherapy options are reported to have significant shortcomings such as being suboptimally active, especially towards the specific form of the parasites, have varying rates of efficacy, have burdensome side effects, need long treatment/administration terms, and the resistance to their action of some parasites [218–220]. Considering this scenario, there is a substantial need to find and promote new potent antiparasitic treatments which are affordable and have minimal adverse reactions.

In recent decades, there has been a keen interest in screening the pharmacological and chemical characteristics of bee-related products, a promising source of natural bioactive substances, as an alternative antiparasitic therapy [221]. Since classical times, bee related products have been popularly used traditionally as herbal remedies for treating some infectious diseases in many communities around the world [222]. In this review, we found that there are four bee-related products i.e., propolis, bee venom, bee pollen and honey that have been extensively studied to uncover their antiparasitic activities against protozoa and worms as the commonest classes of parasites infecting humans. Diverse studies have indicated that bee products are shown to be scientifically effective, via in vitro and/or in vivo tests, in treating a wide variety of infectious diseases such as schistosomiasis, trypanosomiasis (chagas disease), leishmaniasis, toxocarasis, plasmodiasis, toxoplasmisis, blastocystis infection, amebiasis, giardiasis, cryptosporidiosis, and echinococcosis (Table 3).

The curative properties of bee products have been directly associated to their chemical components. However, the chemical constituents of bee products are complex and differ according to their botanical source and geographical origins as indicated by the regional variations in the antiparasitic activities of the bee products [223–225]. Other factors reported to influence the dissimilarity of the physicochemical characteristics of the bee products are the vegetation surrounding the beehive, collection time, soil diversity, geoclimatic conditions or seasons in the collection area, the bee species, and particular flora living at the harvesting location [226–228]. Variations in the concentration of effective bee products are also predominantly affected by the type and origins of parasites used in
the experiments as well as the preparation method [198,229,230]. There is a wide range of the extraction method applied to obtain, for example, propolis extracts ranging from conventional separation technique using organic solvent such as ethanol to a more sophisticated one such as a supercritical fluid extraction method [231]. The extraction methods can influence the amount of active substances in the extract and therefore, might change the biological activities of the extracts [231]. Lastly, the type of bee products also determines the magnitude of biological properties. Some studies indicated that different varieties of Brazilian propolis such as red, green, and brown have distinct chemical compounds and therefore, have a different potency against parasites parasitizing humans [198,232].

There are several proposed pharmacological mechanism of bee products to act against protozoan infections which are deemed to be facilitated by their flavonoid and phenolic constituents as follows [233–235]: (1) Activation of macrophages which kills the parasite via the production of ROS (particularly superoxide dismutase) and nitrogen metabolites [236,237]; (2) The alteration of angiogenesis in the affected tissue [236,238]; (3) Stimulation of immunomodulatory effects, by influencing the production of interferon-γ, tumor necrosis factor α, IL-1, IL-4 and IL-17 [239–241]; (4) Induction of apoptosis-like mechanisms in parasites [236]; (5) Membrane disruption in parasites [242].

Table 3. Antiparasitic effect of selected bee products.

| Bee Products | Country | Parasites | Assay Method | Results | Refs. |
|--------------|---------|-----------|--------------|---------|-------|
| Propolis extracts (12 samples from different location in Libya) | Libya | Trypanosoma brucei (s427); Leishmania donovani; Plasmodium falciparum | In vitro | All the extracts are to some extent effective against all of the tested protozoa. There are regional variations in the antiparasitic properties | [223] |
| Ethanolic extracts of European propolis (35 different samples) | Europe | Trypanosoma brucei 427WT; Trypanosoma brucei B45 (resistant strain); Trypanosoma congolense; Leishmania mexicana WT; Leishmania mexicana C12Rx (resistant strain) | In vitro | All extracts display high level activities against the parasites. Yet, there are regional variations in the antiparasitic properties | [225] |
| Hydroethanolic red propolis extracts | Brazil | Trypanosoma cruzi; Leishmania braziliensis varna; Leishmania infantum promastigotes | In vitro | The extracts exhibit strong cytotoxic properties against the protozoan parasites | [227] |
| Ethanolic extracts of red propolis | Brazil | Schistosoma mansoni | In vitro, in vivo | Propolis displays antischistosomal properties by decreasing motility and producing; mortality of adult parasites; morphological disruptions in the schistosomes’ tegument; and substantial impairment in egg generation. Propolis also significantly lower the worm and egg burden in both early and chronic S. mansoni murine infection model | [229] |
| Ethanolic extracts of red propolis | Brazil | Trypanosoma cruzi | In vitro | Ethanolic propolis extracts have high inhibitory activity against T. cruzi | [198] |
| Dry, alcoholic, and glycolic green propolis extracts | Brazil | Leishmania (Vaennia) braziliensis promastigotes and amastigotes | In vitro | The extracts exhibits antileishmanial activity against promastigotes and amastigotes stages of the parasite | [237] |
| Ethanoalcoholic extracts of red and green propolis | Brazil | Leishmania (Vianna) braziliensis | n.a | Both propolis extracts exhibits leishmanicidal effect in a dose-dependent manner. Yet, the red propolis extract displays a higher efficacy than the green extract | [231] |
| Hydroethanolic extract of red propolis | Brazil | Leishmania chagasi promastigote; Leishmania amazonensis promastigote | In vitro | The extract exhibits leishmanicidal potency against the parasites | [243] |
| Hydroalcoholic extract of Brazilian propolis | Brazil | Leishmania (Vaennia) braziliensis | In vitro | Propolis extract shows immunomodulatory effects, by enhancing IL-4 and IL-17 and lowering IL-10, and therefore, may protect against Leishmania infection and clear the parasite | [239] |
Table 3. Cont.

| Bee Products                                      | Country          | Parasites                              | Assay Method       | Results                                                                                                                                  | Refs.  |
|---------------------------------------------------|------------------|----------------------------------------|--------------------|------------------------------------------------------------------------------------------------------------------------------------------|--------|
| Hydroalcoholic extract of Brazilian green propolis| Brazil           | *Leishmania amazonensis* promastigotes and amastigotes | In vitro, In vivo  | Propolis extract decreases the viability of *L. amazonensis* amastigotes and promastigotes. The extract also decreases the parasites and stimulates the macrophage recruitment into the lesion caused by the *L. amazonensis* | [236]  |
| Degradation products of major compounds of green propolis: Z-artepillin C and Z-\(p\)-coumaric Acid | Brazil           | *Leishmania amazonensis* promastigotes and amastigotes | In vitro           | Both Z-artepillin C and Z-\(p\)-coumaric acid display a promising and significant activity against *L. amazonensis*                  | [244]  |
| Hydroalcoholic extract of *Melipona fasciculata* geopropolis | Brazil           | *Leishmania amazonensis* promastigotes and amastigotes | In vitro           | Geopropolis has an antileishmanial effect and effective in reducing the number of the *L. amazonensis* promastigotes and amastigotes | [233]  |
| Isolated compound of Bee pollen monofloral         | Brazil           | *Leishmania amazonensis*                | In vitro           | The isolated compound identified as the biflavonoid rhusflavone shows high antileishmanial effect against *L. amazonensis* promastigotes and amastigotes | [234]  |
| Bee venom and propolis                            | Egypt            | *Schistosoma mansoni*                  | In vivo            | Bee venom and propolis exerts anti-schistosomal activities by substantially lowering the mean total numbers of worm, mean values of immature and mature egg as well as the ova count in hepatic tissue | [245]  |
| Egyptian propolis ethanolic extract               | Egypt            | *Toxocara vitulorum*                   | In vitro           | The extract exhibits anthelmintic efficacy and the nematicidal effect is dose-dependent                                                | [246]  |
| Egyptian propolis ethanolic extract               | Egypt            | *Blastocystis spp.*                    | In vitro           | The extract presents a notable obstructive effect on the growth of *Blastocystis* parasites                                             | [247]  |
| Egyptian propolis ethanolic and water extract     | Egypt            | *Cryptosporidium spp.*                 | In vivo            | The prophylactic and therapeutic administration of the extracts moderately effective in reducing the oocysts shedding on cryptosporidiosis infected rats | [248]  |
| Egyptian propolis ethanolic extract               | Egypt            | *Toxoplasma gondii*                    | In vivo            | Propolis markedly decreases the amount of IL-1\(\beta\), IL-6, and TNF\(\alpha\) in *T. gondii* infected models                      | [249]  |
| Egyptian propolis ethanolic extract               | Egypt            | *Giardia lamblia*                      | In vivo            | Propolis markedly reduce the *G. lamblia* trophozoites count                                                                        | [250]  |
| *Ziziphus spina-christi* honey; *Acacia nilotca* honey; *Acacia seyal* honey; *Cucurbita maxima* honey | Saudi Arabia     | *Entamoeba histolytica; Giardia lamblia* | In vitro           | All honeys are potentially effective to be used as anti amoebic and antigiardial agents since they can halt the growth of the trophozoites | [47]   |
| Ethanol and dichloromethane Propolis extracts     | Iran             | *Plasmodium falciparum*                | In vitro           | All extracts show concentration-dependent anti-plasmodial activity. Dichloromethane extract has the most potent inhibitory effect        | [252]  |
| Ethanol and dichloromethane Propolis extracts     | Iran             | *Leishmania major*                     | In vitro, In vivo  | Both tests indicate that the extract has an effective antileishmanial activity against *L. major*. The extract reduces the number of promastigotes and decreases the size of ulcers significantly | [253]  |
| Ethanol extract of Algerian propolis              | Algeria          | *Echinococcus granulosus*              | In vitro, In vivo  | Both tests indicate that the extract is an effective antihydatic scolicidal effect since it has a major scolicidal activity against *E. granulosus* at all tested concentration and reduces cystic echinococcosis development in in vivo model | [254]  |
| Methanolic extracts of propolis (ten different propolis from different geographical area in Bolivia) | Bolivia          | *Leishmania amazonensis; Leishmania braziliensis* | In vitro           | All propolis extracts show growth inhibition against both protozoa. Propolis with rich phenolic contents shows the best antiprotozoal effect | [255]  |
| Bee Products                                                                 | Country                  | Parasites                                                                 | Assay Method | Results                                                                                           | Refs. |
|----------------------------------------------------------------------------|--------------------------|---------------------------------------------------------------------------|--------------|---------------------------------------------------------------------------------------------------|-------|
| Methanolic extracts of propolis (three different propolis from different geographical area in Ecuador) | Ecuador                  | *Leishmania amazonensis*                                                  | In vitro     | All propolis extracts show growth inhibition against the protozoa. Propolis with the richest flavonoids contents shows the best antiprotozoal effect | [235] |
| Ethanol extracts of propolis (twelve different propolis from eight different geographical area in Nigeria) | Nigeria                  | *Trypanosoma brucei* (<s427, wild-type); *Trypanosoma brucei* (B48, resistant strain); *Trypanosoma brucei* (aqp2/aqp3 null, resistant strain) | In vitro     | The extracts are active against all the tested parasites                                           | [224] |
| Isolated phenolic compounds of Nigerian red propolis                        | Nigeria                  | *Trypanosoma brucei* (<s427, wild-type); *Trypanosoma brucei* (B48, resistant strain); *Trypanosoma brucei* (aqp2/aqp3 null, resistant strain) | In vitro     | The extract displays moderate to high antitrypanosomal effectivity against all the tested parasites | [256] |
| Tanzanian propolis ethanolic extract                                        | Tanzania                 | *Trypanosoma brucei* (<s427, wild-type); *Trypanosoma brucei* (B48, resistant strain) | In vitro     | The extract displays antitrypanosomal potency against both parasites                              | [257] |
| Zambian propolis ethanolic extract                                          | Zambia                   | *Trypanosoma brucei* (<s427, wild-type); *Trypanosoma brucei* (B48, resistant strain) | In vitro     | The extract displays antitrypanosomal activity against the wild type of *T. brucei* and the multi-drug resistant clone | [257] |

6. Bee Product-Derived Nanoparticles as Potential Therapeutic Agents

Green chemistry principles have recently received much attention for their use in creating biocompatible nanomaterials. Due to the presence of phytoconstituents as stabilizing ligands on their surfaces, nanoparticles prepared by the application of natural product extracts have frequently demonstrated promising bioactivity. Honey bee products such as honey, royal jelly, bee venom, pollen, and beeswax are thought to be promising sources of products to avoid nanoparticle aggregation thus improving the biocompatibility, stability, and biological application. It is possible to functionalize these nanomaterial biomolecules. Metal nanoparticles such as platinum, gold, silver, zinc and others are commonly used nanoparticles in the biomedicine sector. The bactericidal and inhibitory properties of Ag NPs-based nanoparticles against various microbes are quite impressive, along with their high efficiency, strong biocompatibility, easy availability, and low cost which, made them gain significant consideration to scientists and technologists [258].

Al-Yousef et al. prepared Ag NPs (AgNPs-G) using bee pollen aqueous extract as a bioreductant during the experiments and found that they demonstrated excellent antioxidant properties and worked against different Gram-positive and negative bacteria. They even successfully exerted an anti-proliferative effect against cancer cell lines, including MCF-7 and HepG2 [259]. Magnetite nanoparticles are another type of nanoparticle with antimicrobial properties. According to El-Guendouz et al. magnetite nanoparticles twinned with propolis shows antimicrobial activities against methicillin-resistant strains of *S. aureus* [260]. Honey is another bee product that has antimicrobial, anti-inflammatory, and antioxidant properties. Chen et al. reported a new bioactive component-vesicle-like nanoparticles (H-VLNs) in honey that shows anti-inflammatory activities [261]. H-VLNs can disrupt a crucial inflammatory signaling platform in the innate immune system by restraining the formation and activation of the nucleotide-binding domain and pyrin domain-containing 3 (NLRP3) inflammasome. In mice, these nanoparticles reduced inflammation and liver damage in an experimentally induced acute liver injury model [261].

Like metal nanoparticles, polymeric nanoparticles and liposomes are other types of nanoparticles that are a popular choice as drug delivery vehicles for therapeutic applications in the pharmaceutical area and are safe. A study conducted by Iadnut et al. concluded that ethanolic extract of propolis loaded with polymeric nanoparticles pro-
foundly inhibited the growth of Candida albicans [262]. They found that the ethanolic extract of propolis-loaded poly(lactic-co-glycolic acid) nanoparticles can reduce gene-encoding virulence-associated hyphal adhesion proteins of C. albicans, which further attenuates the fungal virulence [262]. In another study, do Nascimento et al. investigated the immuno-suppressive activity of “multiple-constituent extract in the co-delivery system” against leishmaniasis by loading using Brazilian red propolis extract into polymeric nanoparticles [263]. Various dosage forms of red propolis extract loaded with nanoparticles were tested and discovered to be a potential intermediate product for the preparation of various drugs for diseases like leishmaniasis.

Bee venom is gaining popularity for its antipathogenic, anticancer, anti-tumor activities. Alalawy et al. prepared fungal chitosan nanoparticles loaded with bee venom and demonstrated that such bee-venom nanoparticle preparation was significantly potent as a natural anti-proliferative agent against cervical cancer [28]. In addition to that, Saber et al. used bee venom loaded with chitosan to successfully treat amoebiasis in mice [264], indicating that, bee venom possesses antiparasitic properties in addition to its anticancer properties.

7. Concluding Remarks and Future Directions

Bee products such as honey, propolis, bee pollen, royal jelly, bee bread, beeswax, and bee venom have been broadly used in traditional healing practices. With their potential medical and pharmaceutical properties, increasing interest in bee products has been seen in the last century. With the advancements in research tools and our great progress in the understanding of biological processes, the main active component(s) responsible for the anticancer, antibacterial, antiviral as well as antiparasitic properties of bee products need to be clearly elucidated in a standardized way in order to improve the application of bee products in disease management. The issue of standardization has also been hampering the use of bee products not only in pharmaceuticals but also in cosmetics and food industries. Furthermore, there is also a need to determine the optimal dose of bee products and how to use the products to treat cancer as well as infections. This information is substantial in order to bridge the experimental results from the bench to the bedside.

Author Contributions: Conceptualization, F.N., T.B.E., J.S.-G.; methodology, investigation, resources, F.N., A.M., M.A.B., M.R., T.B.E. and J.S.-G.; writing—original draft preparation, F.N., A.M., M.A.B., M.R., S.R.P., S.M., T.B.E. and J.S.-G.; together with writing—review & editing, correspondence, F.N., T.B.E. and J.S.-G. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Available data are presented in the manuscript.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Samarghandian, S.; Farkhondeh, T.; Samini, F. Honey and Health: A Review of Recent Clinical Research. Pharmacogn. Res. 2017, 9, 121–127. [CrossRef]
2. Al-Hatamleh, M.A.I.; Boer, J.C.; Wilson, K.L.; Plebanski, M.; Mohamud, R.; Mustafa, M.Z. Antioxidant-Based Medicinal Properties of Stingless Bee Products: Recent Progress and Future Directions. Biomolecules 2020, 10, 923. [CrossRef]
3. Cornara, L.; Biagi, M.; Xiao, J.; Burlando, B. Therapeutic Properties of Bioactive Compounds from Different Honeybee Products. Front. Pharm. 2017, 8, 412. [CrossRef]
4. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jamal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021, 71, 209–249. [CrossRef]
5. Münstedt, K.; Männle, H. Bee products and their role in cancer prevention and treatment. Complement. Ther. Med. 2020, 51, 102390. [CrossRef]
6. Afrin, S.; Haneefa, S.M.; Fernandez-Cabezudo, M.J.; Giampieri, F.; Al-Ramadi, B.K.; Battino, M. Therapeutic and preventive properties of honey and its bioactive compounds in cancer: An evidence-based review. Nutr. Res. Rev. 2020, 33, 50–76. [CrossRef]
34. Viuda-Martos, M.; Pérez-Alvarez, J.A.; Fernández-López, J. Royal Jelly: Health Benefits and Uses in Medicine. In Bee Products—Chemical and Biological Properties; Alvarez-Suarez, J.M., Ed.; Springer International Publishing: Cham, Switzerland, 2017; pp. 199–218. [CrossRef]

35. Siheri, W.; Alenezi, S.; Tusiimire, J.; Watson, D.G. The Chemical and Biological Properties of Propolis. In Bee Products—Chemical and Biological Properties; Alvarez-Suarez, J.M., Ed.; Springer International Publishing: Cham, Switzerland, 2017; pp. 137–178. [CrossRef]

36. Abd El-Wahed, A.A.; Khalifa, S.A.M.; Sheikh, B.Y.; Farag, M.A.; Saeed, A.; Larik, F.A.; Koca-Caliskan, U.; AlAjmi, M.F.; Hassan, M.; Wahabi, H.A.; et al. Bee Venom Composition: From Chemistry to Biological Activity. In Studies in Natural Products Chemistry; Attia, ur, R., Ed.; Elsevier: Amsterdam, The Netherlands, 2019; Volume 60, pp. 459–484.

37. Hassan, M.I.; Mohamed, A.F.; Amer, M.A.; Hammad, K.M.; Riad, S.A. Monitoring of the antiviral potential of bee venom and wax extracts against Adeno-7 (DNA) and Rift Valley fever virus (RNA) viruses models. J. Egypt Soc. Parasitol. 2015, 45, 193–198. [CrossRef]

38. Uddin, M.B.; Lee, B.H.; Nikapitiya, C.; Kim, J.H.; Kim, T.H.; Lee, H.C.; Kim, C.G.; Lee, J.S.; Kim, C.J. Inhibitory effects of bee venom and its components against viruses in vitro and in vivo. J. Microbiol. 2016, 54, 853–866. [CrossRef] [PubMed]

39. Aw Yong, P.Y.; Islam, F.; Harith, H.H.; Israf, D.A.; Tan, J.W.; Tham, C.L. The Potential use of Honey as a Remedy for Allergic Diseases: A Mini Review. Front. Pharm. 2020, 11, 599080. [CrossRef] [PubMed]

40. Santos-Buelga, C.; González-Paramás, A.M. Chemical Composition of Honey. In Bee Products—Chemical and Biological Properties; Alvarez-Suarez, J.M., Ed.; Springer International Publishing: Cham, Switzerland, 2017; pp. 43–82. [CrossRef]

41. Gündoğdu, E.; Cakmakci, S.; Şat,˙I. An Overview of Honey: Its Composition, Nutritional and Functional Properties. J. Food Compos. Anal. 2019, 9, 10–14. [CrossRef]

42. Sousa, J.M.; de Souza, E.L.; Marques, G.; Meireles, B.; de Magalhães Cordeiro, Á.T.; Gullón, B.; Pintado, M.M.; Magnani, M. Polyphenolic profile and antioxidant and antibacterial activities of monofloral honeys produced by Meliponini in the Brazilian semiarid region. Food Res. Int. 2016, 84, 61–68. [CrossRef]

43. Ahmed, S.; Sulaiman, S.A.; Baig, A.A.; Ibrahim, M.; Liaqat, S.; Fatima, S.; Jabeen, S.; Shamim, N.; Othman, N.H. Honey as a Potential Natural Antioxidant Medicine: An Insight into Its Molecular Mechanisms of Action. Oxid. Med. Cell Longev. 2018, 2018, 8367846. [CrossRef]

44. Alqarni, A.S.; Owayss, A.A.; Mahmoud, A.A.; Hannan, M.A. Mineral content and physical properties of local and imported honeys in Saudi Arabia. J. Saudi Chem. Soc. 2014, 18, 618–625. [CrossRef]

45. Rao, P.V.; Krishnan, K.T.; Salleh, N.; Gan, S.H. Biological and therapeutic effects of honey produced by honey bees and stingless bees: A comparative review. Rev. Bras. De Farmacogn. 2016, 26, 657–664. [CrossRef]

46. Piszcz, P.; Glöö, B.K. Antioxidative Properties of Selected Polish Honeys. J. Apic. Sci. 2019, 63, 81–91. [CrossRef]

47. Mohammed, S.E.A.; Kabbashi, A.S.; Koko, W.S.; Ansari, M.J.; Adgaba, N.; Al-Ghamdi, A. In vitro activity of some natural honeys against Entamoeba histolytica and Giardia lamblia trophozoites. Saudi J. Biol. Sci. 2019, 26, 238–243. [CrossRef]

48. Cocot, J.; Kiełczykowska, M.; Luchowska-Kocot, D.; Kurzepa, J.; Musik, I. Antioxidant Potential of Propolis, Bee Pollen, and Royal Jelly: Possible Medical Application. Oxid. Med. Cell. Longev. 2018, 2018, 7074209. [CrossRef]

49. Pasupuleti, V.R.; Sammugam, L.; Ramesh, N.; Gan, S.H. Honey, Propolis, and Royal Jelly: A Comprehensive Review of Their Biological Actions and Health Benefits. Oxid. Med. Cell. Longev. 2017, 2017, 1259510. [CrossRef]

50. Bonamigo, T.; Campos, J.F.; Alfredo, T.M.; Balestieri, J.B.P.; Cardoso, C.A.L.; Paredes-Gamero, E.J.; de Picoli Souza, K.; dos Santos, E.L. Antioxidant, Cytotoxic, and Toxic Activities of Propolis from Two Native Bees in Brazil: Scaptotrigona depilis and Melipona quadrifasciata antidioides. Oxid. Med. Cell. Longev. 2017, 2017, 1038153. [CrossRef] [PubMed]

51. Huang, S.; Zhang, C.P.; Wang, K.; Li, G.Q.; Hu, F.L. Recent advances in the chemical composition of propolis. Molecules 2014, 19, 9610. [CrossRef]

52. Hashem, N.M.; Hassanein, E.M.; Simal-Gandara, J. Improving Reproductive Performance and Health of Mammals Using Honeybee Products. Antioxidants 2021, 10, 336. [CrossRef] [PubMed]

53. Wang, X.; Sankarapandian, K.; Cheng, Y.; Woo, S.O.; Kwon, H.W.; Perumalsamy, H.; Ahn, Y.-J. Relationship between total phenolic contents and biological properties of propolis from 20 different regions in South Korea. BMC Complement. Altern. Med. 2016, 16, 65. [CrossRef]

54. El-Seedi, H.R.; Khalifa, S.A.M.; El-Wahed, A.A.; Gao, R.; Guo, Z.; Tahir, H.E.; Zhao, C.; Du, M.; Farag, M.A.; Musharraf, S.G.; et al. Honeybee products: An updated review of neurological actions. Trends Food Sci. Technol. 2020, 101, 17–27. [CrossRef]

55. Takashima, M.; Ichihara, K.; Hirata, Y. Neuroprotective effects of Brazilian green propolis on oxytosis/ferroptosis in mouse hippocampal HT22 cells. Food Chem. Toxicol. 2019, 132, 110669. [CrossRef]

56. Berretta, A.A.; Silveira, M.A.D.; Cónord Capcha, J.M.; De Jong, D. Propolis and its potential against SARS-CoV-2 infection mechanisms and COVID-19 disease. Biomed. Pharmacother. 2020, 131, 110622. [CrossRef]

57. Vasconcelos, M.R.D.S.; Duarte, A.W.F.; Gomes, E.P.; Silva, S.C.D.; López, A.M.Q. Physicochemical composition and antioxidant potential of bee pollen from different botanical sources in Alagoas, Brazil. Ciência E Agrotecnologia 2017, 41, 447–458. [CrossRef]

58. Thakur, M.; Nanda, V. Composition and functionality of bee pollen: A review. Trends Food Sci. Technol. 2020, 98, 82–106. [CrossRef]

59. Gardana, C.; Del Bo’, C.; Quicazán, M.C.; Correa, A.R.; Simonetti, P. Nutrients, phytochemicals and botanical origin of commercial bee pollen from different geographical areas. J. Food Compos. Anal. 2018, 73, 29–38. [CrossRef]
85. Kieliszek, M.; Piwowarek, K.; Kot, A.M.; Blażejak, S.; Chlebowska-Śmigielska, A.; Wolska, I. Pollen and bee bread as new health-oriented products: A review. *Trends Food Sci. Technol.* 2018, 71, 170–180. [CrossRef]

86. Khalifa, S.A.M.; Elshal, M.; Kieliszek, M.; Ghazala, N.E.; Farag, M.A.; Saeed, A.; Xiao, J.; Zou, X.; Khatib, A.; Göransson, U.; et al. Recent insights into chemical and pharmacological studies of bee bread. *Trends Food Sci. Technol.* 2020, 97, 300–316. [CrossRef]

87. Mayda, N.; Özkök, A.; Ecem Bayram, N.; Gerdüz, Y.C.; Sorkun, K. Bee bread and bee pollen of different plant sources: Determination of phenolic content, antioxidant activity, fatty acid and element profiles. *J. Food Meas. Charact.* 2020, 14, 1795–1809. [CrossRef]

88. Kaplan, M.; Karaoglu, O.; Ergul, N.; Silici, S. Fatty Acid and Proximate Composition of Bee Bread. *Food Technol. Biotechnol.* 2016, 54, 497–504. [CrossRef] [PubMed] [PubMed]

89. Sobral, F.; Calhelha, R.C.; Barros, L.; Duena, M.; Tomás, A.; Santos-Buelga, C.; Vilas-Boas, M.; Ferreira, I.C. Flavonoid Composition and Antitumor Activity of Bee Bread Collected in Northeast Portugal. *Molecules* 2017, 22, 248. [CrossRef]

90. Bakour, M.; Al-Waili, N.S.; El Meniy, N.; Imtara, H.; Xiao, J.; Zou, X.; Khatib, A.; Göransson, U.; et al. Recent insights into chemical and pharmacological studies of bee bread. *Trends Food Sci. Technol.* 2020, 97, 300–316. [CrossRef]

91. Kaškonienė, V.; Adaškevičiutė, V.; Kaškonas, P.; Mickienė, R.; Maruška, A. Antimicrobial and antioxidant activities of natural and fermented bee pollen. *Food Biosci.* 2020, 34, 100532. [CrossRef] [PubMed] [PubMed]

92. Pucca, M.B.; Cerni, F.A.; Oliveira, I.S.; Jenkins, T.P.; Argemi, L.; Sørensen, C.V.; Ahmad, S.; Barbosa, J.E.; Laustsen, A.H. Bee Updated: Current Knowledge on Bee Venom and Bee Envenoming Therapy. *Front. Immunol.* 2019, 10. [CrossRef] [PubMed]

93. Elieh Ali Komi, D.; Shafaghat, F.; Zwiener, R.D. Immunology of Bee Venom. [CrossRef] [PubMed]

94. Lee, K.S.; Kim, B.Y.; Yoon, H.J.; Choi, Y.S.; Jin, B.R. Secapin, a bee venom peptide, exhibits anti-fibrinolytic, anti-elastolytic, and anti-microbial activities. *Dev. Comp. Immunol.* 2016, 63, 27–35. [CrossRef]

95. Mohamed, W.A.; Abd-Elhakim, Y.M.; Ismail, S.A.A. Involvement of the anti-inflammatory, anti-apoptotic, and anti-secretory activity of bee venom in its therapeutic effects on acetylsalicylic acid-induced gastric ulceration in rats. *Toxicology* 2019, 419, 11–23. [CrossRef]

96. Mohamed, W.A.; Abd-Elhakim, Y.M.; Ismail, S.A.A. Involvement of the anti-inflammatory, anti-apoptotic, and anti-secretory activity of bee venom in its therapeutic effects on acetylsalicylic acid-induced gastric ulceration in rats. *Toxicology* 2019, 419, 11–23. [CrossRef]

97. Zhang, S.; Liu, Y.; Ye, Y.; Wang, X.R.; Lin, L.T.; Xiao, L.Y.; Zhou, P.; Shi, G.X.; Liu, C.Z. Bee venom therapy: Potential mechanisms and therapeutic applications. *Toxicon* 2018, 148, 64–73. [CrossRef]

98. Sawczuk, R.; Karpinska, J.; Miltyk, W. What do we need to know about drone brood homogenate and what is known. *J. Ethnopharmacol.* 2019, 245, 111581. [CrossRef] [PubMed]

99. Sidor, E.; Dzugan, M. Drone Brood Homogenate as Natural Remedy for Treating Health Care Problem: A Scientific and Practical Approach. *Molecules* 2020, 25, 5699. [CrossRef] [PubMed]

100. Imtara, H.; Kmail, A.; Touzani, S.; Khader, M.; Hamarshi, H.; Saad, B.; Lyoussi, B. Chemical analysis and cytotoxic and cytostatic effects of twelve honey samples collected from different regions in morocco and palestine. *Evid. Based Complement. Altern. Med.* 2019, 2019, 1–11. [CrossRef] [PubMed]

101. Portokalakis, I.; Yusof, H.I.M.; Ghanotakis, D.F.; Nigam, P.S.; Owusu-Apenten, R. Manuka honey-induced cytotoxicity against MF7 breast cancer cells is correlated to total phenol content and antioxidant power. *J. Adv. Biol. Biotechnol.* 2016, 1–10. [CrossRef]

102. Aryappalli, P.; Al-Qubaisi, S.S.; Attoub, S.; George, J.A.; Arafat, K.; Ramadi, K.B.; Mohamed, Y.A.; Al-Dhaheri, M.M.; Al-Sbiei, A.; Fernandez-Cabezudo, M.J. The IL-6/STAT3 signaling pathway is an early target of manuka honey-induced suppression of human breast cancer cells. *Front. Oncol.* 2017, 7, 167. [CrossRef] [PubMed]

103. Henderson, K.; Airdhigam, T.; Nigam, P.S.-N.; Owusu-Apenten, R.K. Evaluation of Manuka honey estrogon activity using the MCF-7 cell proliferation assay. *J. Adv. Biol. Biotechnol.* 2016, 10, 1–11. [CrossRef]

104. Aumeeruddy, M.Z.; Aumeeruddy-Elali, Z.; Neetoo, H.; Zengin, G.; van Staden, A.B.; Fribich, B.; Lambrechts, I.A.; Rademan, S.; Szuman, K.M.; Lall, N. Pharmacological activities, chemical profile, and physicochemical properties of raw and commercial honey. *Biocatal. Agric. Biotechnol.* 2019, 18, 101005. [CrossRef]

105. Salleh, M.A.M.; Eshak, Z.; Ismail, W.W. Acacia honey induces apoptosis in human breast adenocarcinoma cell lines (MCF-7). *J. Teknol.* 2017, 79, 9–16. [CrossRef]

106. Kaya, B.; Yildirim, A. Determination of the antioxidant, antimicrobial and anticancer properties of the honey phenolic extract of five different regions of Bingol province. *J. Food Sci. Technol.* 2021, 58, 2420–2430. [CrossRef] [PubMed]

107. Waheed, M.; Hussain, M.B.; Javed, A.; Mushra, Z.; Hassan, S.; Shariati, M.A.; Khan, M.U.; Majeed, M.; Nigam, M.; Mishra, A.P. Honey and cancer: A mechanistic review. *Clin. Nutr.* 2019, 38, 2499–2503. [CrossRef]

108. da Silva, P.M.; Gauthier, C.; Gonzaga, L.V.; Costa, A.C.O.; Fett, R. Honey: Chemical composition, stability and authenticity. *Food Chem.* 2016, 196, 309–323. [CrossRef]

109. Machado De-Melo, A.A.; Almeida-Muradian, L.B.D.; Sancho, M.T.; Pascual-Maté, A. Composition and properties of Apis mellifera honey: A review. *J. Apiac. Res.* 2018, 57, 5–37. [CrossRef]

110. Biluca, F.C.; da Silva, B.; Caon, T.; Mohr, E.T.B.; Vieira, G.N.; Gonzaga, L.V.; Vitali, L.; Micke, G.; Fett, R.; Dalmacco, E.M. Investigation of phenolic compounds, antioxidant and anti-inflammatory activities in stingless bee honey (Meliponinae). *Food Res. Int.* 2020, 129, 108756. [CrossRef] [PubMed]
111. Beretta, G.; Moretti, R.M.; Nasti, R.; Cincinelli, R.; Dallavalle, S.; Marelli, M.M. Apoptosis-mediated anticancer activity in prostate cancer cells of a chestnut honey (*Castanea sativa* L.) quinoline–pyrroolidine gamma-lactam alkaloid. *Amino Acids* **2021**, *53*, 869–880. [CrossRef]

112. Fauzi, A.N.; Yaacob, N.S. Cell cycle and apoptosis pathway modulation by Tualang honey in ER-dependent and -independent breast cancer cell lines. *J. Apic. Res.* **2016**, *55*, 366–374. [CrossRef]

113. Su, M.; Chang, W.; Zhang, K.; Cui, M.; Wu, S.; Xu, T. Expression and purification of recombinant ATF-mellitin, a new type fusion protein targeting ovarian cancer cells, in *P. pastoris* protein targeting ovarian cancer cells, in *P. pastoris* protein targeting ovarian cancer cells, in *P. pastoris* protein targeting ovarian cancer cells. *Front. Pharmacol.* **2016**, *7*, 104. [CrossRef] [PubMed]

114. Elnakady, Y.A.; Rushdi, A.I.; Franke, R.; Abutaha, N.; Ebaid, H.; Baabbad, M.; Omar, M.O.M.; Al Ghamdi, A.A. Characteristics, chemical compositions and biological activities of propolis from Al-Bahah, Saudi Arabia. *Sci. Rep.* **2017**, *7*, 1–13. [CrossRef] [PubMed]

115. Nouroeddine, H.; Hage-Sleiman, R.; Wehbi, B.; Fayyad-Kazan, H.; Hayar, S.; Traboulssi, M.; Alyamani, O.A.; Faour, W.H.; Elmahour, Y. Chemical characterization and cytotoxic activity evaluation of Lebanese propolis. *Biomed. Pharmacother.* **2017**, *95*, 298–307. [CrossRef] [PubMed]

116. Czyżewska, U.; Siemionow, K.; Zareba, I.; Mityyk, W. Proapoptotic activity of propolis and their components on human tongue squamous cell carcinoma cell line (CAL-27). *PloS ONE* **2016**, *11*, e0157091. [CrossRef]

117. Touzani, S.; Embaslat, W.; Imtara, H.; Khail, A.; Kadan, S.; Zaid, H.; ElArabi, I.; Badiaa, L.; Saad, B. In vitro evaluation of the potential use of propolis as a multitarget therapeutic product: Physicochemical properties, chemical composition, and immunomodulatory, antibacterial, and anticancer properties. *BioMed Res. Int.* **2019**, *2019*, 1–11. [CrossRef] [PubMed]

118. Celińska-Janowicz, K.; Zaręba, I.; Lazarek, U.; Teul, J.; Tomczyk, M.; Pałka, J.; Miltyk, W. Constituents of propolis: Chrysin, caffeic acid, p-coumaric acid, and ferulic acid induce PRODH/POX-dependent apoptosis in human tongue squamous cell carcinoma cell (CAL-27). *Front. Pharmacol.* **2018**, *9*, 336. [CrossRef]

119. Sun, L.; Guo, Y.; Zhang, Y.; Zhuang, Y. Antioxidant and anti-tyrosinase activities of phenolic extracts from rape bee pollen and inhibitory melanogenesis by cAMP/MITF/TYR pathway in B16 mouse melanoma cells. *Front. Pharmacol.* **2017**, *8*, 104. [CrossRef] [PubMed]

120. Zou, Y.; Hu, J.; Huang, W.; Zhu, L.; Shao, M.; Dordoe, C.; Ahn, Y.-J.; Wang, D.; Zhao, Y.; Xiong, Y. The botanical origin and antioxidant, anti-BACE1 and antiproliferative properties of bee pollen from different regions of South Korea. *BMC Complement. Med. Ther.* **2020**, *20*, 236. [CrossRef] [PubMed]

121. Saisavoey, T.; Sangtanoo, P.; Srimongkol, P.; Reamtong, O.; Karnchanatat, A. Hydrolysates from bee pollen could induced apoptotic activity of human tongue squamous cell carcinoma (CHA-GO-K-I) to several human cell lines: HeLa, WiDr and Vero. *J. Chem. Pharm. Sci* **2016**, *9*, 336. [CrossRef] [PubMed]

122. Liu, C.-C.; Hao, D.-J.; Zhang, Q.; An, J.; Zhao, J.-J.; Chen, B.; Zhang, L.-L.; Yang, H. Application of bee venom and its main constituent melittin for cancer treatment. *Cancer Chemother. Pharmacol.* **2016**, *78*, 1113–1130. [CrossRef] [PubMed]

123. Moga, M.A.; Diminescu, O.G.; Arvătescu, C.A.; Ifteni, P.; Pleș, L. Anticancer activity of toxins from bee and snake venom—An overview on ovarian cancer. *Molecules* **2018**, *23*, 692. [CrossRef]

124. Sangboonruang, S.; Kitidee, K.; Chantawannakul, P.; Tragoolpua, K.; Tragoolpua, K.; Melittin from *Apis flavus* Venom as a Promising Anticancer Agent. *Antibiotics* **2020**, *9*, 517. [CrossRef] [PubMed]

125. Plassay, M.; Wahid, S.; Natzir, R.; Miskad, U.A. Selective cytotoxicity Assay in anticancer drug of Melittin Isolated from Bee Venom (*Apis cerana indica*) to several human cell lines: HeLa, WiDr and Vero. *J. Chem. Pharm. Sci* **2016**, *9*, 2674–2676. [CrossRef]

126. Zolfagharian, H.; Khalilifard Borojeni, S.; Babaie, M. Evaluation of anticancer effects induced by *Apis mellifera* venom on breast cancer cell line. *Alborz Univ. Med. J.* **2020**, *9*, 357–366. [CrossRef] [PubMed]

127. Mahmoodzadeh, A.; Zarrinnahad, H.; Bagheri, K.P.; Moradia, A.; Shahbazzadeh, D. First report on the isolation of melittin from Iranian honey bee venom and evaluation of its toxicity on gastric cancer AGS cells. *J. Chin. Med. Assoc.* **2020**, *9*, 366–374. [CrossRef] [PubMed]

128. Hou, K.K.; Pan, H.; Lanza, G.M.; Wickline, S.A. Melittin derived peptides for nanoparticle based siRNA transfection. *Biomaterials* **2013**, *34*, 3110–3119. [CrossRef]

129. Yu, X.; Dai, Y.; Zhao, Y.; Qi, S.; Liu, L.; Lu, L.; Luo, Q.; Zhang, Z. Melittin-lipid nanoparticles target to lymph nodes and elicit a systemic anti-tumor immune response. *Nat. Commun.* **2020**, *11*, 1–14. [CrossRef]

130. Holle, L.; Song, W.; Holle, E.; Wei, Y.; Wagner, T.; Yu, X. A matrix metalloproteinase 2 cleavable melittin/avidin conjugate specifically targets tumor cells in vitro and in vivo. *Int. J. Oncol.* **2003**, *22*, 93–98. [CrossRef] [PubMed]

131. Su, M.; Chang, W.; Zhang, K.; Cui, M.; Wu, S.; Xu, T. Expression and purification of recombinant ATf-melittin, a new type fusion protein targeting ovarian cancer cells, in *P. pastoris*. *Oncol. Rep.* **2016**, *35*, 1179–1185. [CrossRef] [PubMed]

132. Zhang, S.; Shao, Q.; Geng, H.; Su, S. The effect of royal jelly on the growth of breast cancer in mice. *Oncol. Lett.* **2017**, *14*, 7615–7621. [CrossRef]

133. Miyata, Y.; Sakai, H. Anti-cancer and protective effects of royal jelly for therapy-induced toxicities in malignancies. *Int. J. Mol. Sci.* **2018**, *19*, 3270. [CrossRef] [PubMed]

134. Filipić, B.; Gradišnik, L.; Rihar, K.; Šošo, E.; Pereyra, A.; Potokar, J. The influence of royal jelly and human interferon-alpha (HuIFN-α(N3)) on proliferation, glutathione level and lipid peroxidation in human colorectal adenocarcinoma cells in vitro. *Arh. Za Hig. Rada I Toksikol.* **2015**, *66*, 66. [CrossRef]

135. Miyata, Y.; Ohba, K.; Matsuo, T.; Mitsunari, K.; Sakai, H. A randomized, double-blinded clinical trial of royal jelly intake for anticancer effects and suppressing adverse events in renal cell carcinoma patients treated with tyrosine kinase inhibitors. *J. Clin. Oncol.* **2020**, *38*, 697. [CrossRef]
136. Araki, K.; Miyata, Y.; Ohba, K.; Nakamura, Y.; Matsuo, T.; Mochizuki, Y.; Sakai, H. Oral intake of royal jelly has protective effects against tyrosine kinase inhibitor-induced toxicity in patients with renal cell carcinoma: A randomized, double-blinded, placebo-controlled trial. *Medicines* 2019, *6*, 2. [CrossRef]

137. Osaka, H.; Abdullah, A.; Gamal, B.; Emad, D.; Sayed, D.; Hussein, E.; Mahfouz, E.; Tharwat, J.; Sayed, S.; Medhat, S. Effect of honey and royal jelly against cisplatin-induced nephrotoxicity in patients with cancer. *J. Am. Coll. Nutr.* 2017, *36*, 342–346. [CrossRef]

138. Wang, S.-Y.; Chen, C.-W. Effects of royal jelly extracts on growth inhibition, differentiation human leukemic U937 cells and its immunomodulatory activity. *BioCell* 2019, *43*, 29–41.

139. Elsayed, N.; El-Din, H.S.; Altemimi, A.B.; Ahmed, H.Y.; Prapat-Singh, A.; Abedelmaksoud, T.G. In Vitro Antimicrobial, Antioxidant and Anticaner Actions of Egyptian Citrus Beebread. *Molecules* 2021, *26*, 2433. [CrossRef] [PubMed]

140. Aru, B.; Güzelmeric, E.; Akgül, A.; Demirel, G.Y.; Krmizbekmez, H. Antiproliferative activity of chemically characterized propolis from Turkey and its mechanisms of action. *Chem. Biodivers.* 2016, *19*, e1900189. [CrossRef]

141. Emran, T.B.; Uddin, M.M.N.; Rahman, M.A.; Uddin, M.Z.; Islam, M.M. Phytochemical, antimicrobial, cytotoxic, analgesic and anti-inflammatory properties of *Azadirachta indica*: A therapeutic study. *J. Bioanal. Biomed.* 2015, *512*, 1–7. [CrossRef]

142. Udaondo, Z.; Matilla, M.A. Mining for novel antibiotics in the age of antimicrobial resistance. *Microb. Biotechnol.* 2020, *13*, 1702–1704. [CrossRef] [PubMed]

143. Peraman, R.; Sure, S.K.; Dusthackleer, V.N.A.; Chilamakuru, N.B.; Yiragamreddy, P.R.; Pokuri, C.; Kutagulla, V.K.; Chinni, S. Insights on recent approaches in drug discovery strategies and untapped drug targets against drug resistance. *Future J. Pharm. Sci.* 2021, *7*, 56. [CrossRef]

144. Sartini, S.; Permana, A.D.; Sure, S.K.; Dusthackleer, V.N.A.; Chilamakuru, N.B.; Yiragamreddy, P.R.; Pokuri, C.; Kutagulla, V.K.; Chinni, S. Antiviral and anti-inflammatory activities of *Honey, Royal Jelly, and Acyclovir Against HSV-1*. *Heliyon* 2019, *5*, e05798. [CrossRef]

145. Didaras, N.A.; Karatasou, K.; Dimitriou, T.G.; Amoutzias, G.D.; Mossialos, D. Antimicrobial Activity of Bee-Collected Pollen and Beebread: State of the Art and Future Perspectives. *Antibiotics* 2020, *9*, 811. [CrossRef]

146. Combarros-Fuertes, P.; Fresno, J.M.; Estevinho, M.M.; Sousa-Pimenta, M.; Tornadijo, M.E.; Estevinho, L.M. Honey: Another Alternative in the Fight against Antibiotic-Resistant Bacteria? *Antibiotics* 2020, *9*, 774. [CrossRef]

147. Nolan, V.C.; Harrison, J.; Wright, J.E.E.; Cox, J.A.G. Clinical Significance of Manuka and Medical-Grade Honey for Antibiotic-Resistant Infections: A Systematic Review. *Antibiotics* 2020, *9*, 766. [CrossRef]

148. Uddin, M.Z.; Rana, M.S.; Hossain, S.; Dutta, E.; Ferdous, S.; Dutta, M.; Emran, T.B. In vivo neuroprotective, antinociceptive, anti-inflammatory potential in Swiss albino mice and in vitro antioxidant and clot lysis activities of fractionated *Hologarina longifolia* Roxb. bark extract. *J. Complement. Integr. Med.* 2019, *17*, 1–10. [CrossRef]

149. Bucekova, M.; Jardeková, L.; Juricova, V.; Bugarová, V.; Di Marco, G.; Gismondi, A.; Leonardi, D.; Farkasovska, J.; Godocikova, J.; Laho, M.; et al. Antibacterial Activity of Different Blossom Hunies: New Findings. *Molecules* 2019, *24*, 1573. [CrossRef] [PubMed]

150. El Sohaimy, S.A.; Masry, S.H.D.; Shehata, M.G. Physicochemical characteristics of honey from different origins. *Ann. Agric. Sci.* 2015, *60*, 279–287. [CrossRef]

151. Silici, S.; Sagdic, O.; Ekici, L. Total phenolic content, antiradical, antioxidant and antimicrobial activities of Rhododendron honeys. *Food Chem.* 2010, *121*, 238–243. [CrossRef]

152. Al-Hatamleh, M.A.I.; Hatmal, M.M.; Sattar, K.; Ahmad, S.; Mustafa, M.; Bittencourt, M.D.C.; Mohamud, R. Antiviral and Anticancer Activities of Egyptian Citrus Beebread. *Molecules* 2021, *26*, 464–467. [CrossRef]

153. Almasaudi, S. The antibacterial activities of honey. *Sci. World J.* 2014, *2014*, 36, 238–243. [CrossRef] [PubMed]

154. Al-Waili, N.S.; Al-Waili, T.N.; Al-Waili, A.N.; Saloom, K.S. Influence of Natural Honey on Biochemical and Hematological Variables in AIDS: A case study. *Sci. World J.* 2006, *6*, 389430. [CrossRef] [PubMed]
189. Stagos, D.; Soulitsiotis, N.; Tsadila, C.; Papaefrotho, S.; Arvanitis, C.; Ntontos, A.; Karkanta, F.; Adamou-Androulaki, S.; Petrotos, K.; Spandidos, D.A.; et al. Antibacterial and antioxidant activity of different types of honey derived from Mount Olympus in Greece. *Int. J. Mol. Med.* 2018, 42, 726–734. [CrossRef] [PubMed]

190. Das, A.; Datta, S.; Mukherjee, S.; Bose, S.; Ghosh, S.; Dhar, P. Evaluation of antioxidative, antibacterial and probiotic growth stimulatory activities of *Sesamum indicum* honey containing phenolic compounds and lignans. *LWT Food Sci. Technol.* 2015, 61, 244–250. [CrossRef]

191. Almasaudi, S.B.; Al-Nahari, A.A.M.; Abd El-Ghany, E.S.M.; Barbour, E.; Al Muhayawi, S.M.; Al-Jaouni, S.; Azhar, E.; Qari, M.; Qari, Y.A.; Harakeh, S. Antimicrobial effect of different types of honey on *Staphylococcus aureus*. *Saud. J. Biol. Sci.* 2017, 24, 1255–1261. [CrossRef] [PubMed]

192. Kamal, R.; Al-Awami, I.; Tarabishy, N.; Hajri, S.; Al-Otaibi, M.; Al-Rabeah, A.; Al-Hebri, K.; Al-Rafee, M. Evaluation of Propolis and Bee Pollen from Greece. Antioxidant and Antimicrobial Properties. *Evid. Based Complement. Altern. Med.* 2017, 2017, 8144–18167. [CrossRef]

193. Junie, L.; Vica, M.; Mirel, G.; Matei, H. Physico-chemical characterization and activity of different strains isolated from hospitalized patients. *J. Apic. Sci.* 2016, 60, 5–18. [CrossRef]

194. Massaro, C.F.; Simpson, J.B.; Powell, D.; Brooks, P. Chemical composition and antimicrobial activity of honeybee (*Apis mellifera ligustica*) propolis from subtropical eastern Australia. *Sci. Nat.* 2015, 102, 68. [CrossRef]

195. Atsalakis, E.; Chinou, I.; Makropoulou, M.J.; Balestieri, J.B.P.; Cardoso, C.A.L.; Paredes-Gamero, E.J.; Estevinho, L.M.; de Picoli Souza, K.; Santos, E.L.D. Antimicrobial, Anti-Inflammatory, and Cytotoxic Activities of Propolis from the Stingless Bee *Tetragonisca febrigata* (Jataí). *Evid. Based Complement. Altern. Med.* 2015, 2015, 296186. [CrossRef]

196. Regueira, M.S.; Tintino, S.R.; da Silva, A.R.P.; Costa, M.d.S.; Boligon, A.A.; Giannopoulou, E.; Skalicka-Woźniak, K.; Graikou, K.; Widelski, J.; Bankova, V.; Kalofonos, H.; Sivolapenko, G.; Popova, M.; Giannopoulou, E.; et al. Bee Pollen from Greece Antibiotic and Chemical Composition of Propolis from the Región del Maule, Central Chile. *Molecules* 2018, 20, 1814–18167. [CrossRef]

197. Rahman, J.; Tareq, A.M.; Hossain, M.M.; Paul, A.; Chy, M.F.; Emran, T.B. In vivo and in vitro evaluation of pharmacological activities of *Adenia trilobata* (Roxb.). *Biochem. Biophys. Rep.* 2020, 23, 100772. [CrossRef] [PubMed]

198. Chen, Y.-W.; Ye, S.-R.; Ting, C.; Yu, Y.-H. Antibacterial Activity of Propolis. *Food Res. Int.* 2015, 76, 449–457. [CrossRef]

199. Campos, J.F.; Santos, U.P.D.; Rocha, P.D.S.D.; Damiao, M.J.; Baledsteri, J.B.P.; Cardoso, C.A.L.; Paredes-Gamero, E.J.; Estevinho, L.M.; de Picoli Souza, K.; Santos, E.L.D. Antimicrobial, Anti-Inflammatory, and Cytotoxic Activities of Propolis from the Stingless Bee *Tetragonisca febrigata* (Jataí). *Evid. Based Complement. Altern. Med.* 2015, 2015, 296186. [CrossRef]

200. Barua, N.; Aziz, M.A.I.; Tareq, A.M.; Sayeed, M.A.; Alam, N.; ul Alam, N.; Uddin, M.A.; Lyzu, C.; Emran, T.B. In vivo and in vitro evaluation of pharmacological activities of *Adenia trilobata* (Roxb.). *Biochem. Biophys. Rep.* 2020, 23, 100772. [CrossRef] [PubMed]

201. Nina, N.; Quispe, C.; Jiménez-Aspe, F.; Theodoulou, C.; Feresin, G.E.; Lima, B.; Leiva, E.; Schmeda-Hirschmann, G. Antimicrobial Activity, Antioxidant Effect and Chemical Composition of Propolis from the Región del Maule, Central Chile. *Molecules* 2018, 20, 1814–18167. [CrossRef]

202. Al-Ani, I.; Zimmermann, S.; Reichling, J.; Wink, M. Antimicrobial Activities of European Propolis Collected from Various Geographic Origins Alone and in Combination with Antibiotics. *Medicines* 2018, 5, 2. [CrossRef] [PubMed]

203. Popova, M.; Giannopoulou, E.; Skalicka-Woźniak, K.; Graikou, K.; Widelski, J.; Bankova, V.; Kalofonos, H.; Sivolapenko, G.; Gaweł-Beben, K.; Antosiewicz, B.; et al. Characterization and Biologcal Evaluation of Propolis from Poland. *Molecules* 2017, 22, 1159. [CrossRef] [PubMed]

204. Chen, Y.-W.; Ye, S.-R.; Ting, C.; Yu, Y.-H. Antibacterial activity of propolis from Taiwanese green propolis. *J. Food Drug Anal.* 2018, 26, 761–768. [CrossRef] [PubMed]

205. Atsalakis, E.; Chinou, I.; Makropoulou, M.; Karabournioti, S.; Graikou, K. Evaluation of Phenolic Compounds in *Cistus creticus* Bee Pollen from Greece. Antioxidant and Antimicrobial Properties. *Nat. Prod. Commun.* 2017, 12, 1141. [CrossRef]

206. Akhir, R.A.M.; Bakar, M.F.A.; Sanusi, S.B. Antioxidant and antimicrobial activity of stingless bee bread and propolis extracts. *AIP Conf. Proc.* 2017, 1891, 020900. [CrossRef]

207. Rahman, J.; Tareq, A.M.; Hossain, M.M.; Sakib, S.A.; Islam, M.N.; Uddin, A.B.M.N.; Hoque, M.; Nasrin, M.S.; Ali, M.H.; Caiazzo, E.; et al. Biological evaluation, DFT calculations and molecular docking studies on the antidepressive, anxiolytic and antidepressant activity of *Tinospora crispa*. *Phytother. Res.* 2020, 34, 2978–2984. [CrossRef] [PubMed]

208. Popova, M.; Giannopoulou, E.; Skalicka-Woźniak, K.; Graikou, K.; Widelski, J.; Bankova, V.; Kalofonos, H.; Sivolapenko, G.; Gaweł-Beben, K.; Antosiewicz, B.; et al. Characterization and Biological Evaluation of Propolis from Poland. *Molecules* 2017, 22, 1159. [CrossRef] [PubMed]

209. Chen, Y.-W.; Ye, S.-R.; Ting, C.; Yu, Y.-H. Antibacterial activity of propolis from Taiwanese green propolis. *J. Food Drug Anal.* 2018, 26, 761–768. [CrossRef] [PubMed]

210. Al-Ani, I.; Zimmermann, S.; Reichling, J.; Wink, M. Antimicrobial Activities of European Propolis Collected from Various Geographic Origins Alone and in Combination with Antibiotics. *Medicines* 2018, 5, 2. [CrossRef] [PubMed]

211. De Marco, S.; Piccioni, M.; Paglietti, R.; Pietrella, D. Bioactive and Antioxidative Activity of Propolis and Bud Poplar Resins versus *Pseudomonas aeruginosa*. *Evid. Based Complement. Altern. Med.* 2017, 2017, 5163575. [CrossRef]

212. Bittencourt, M.L.F.; Ribeiro, P.R.; Franco, R.L.P.; Hilhorst, H.W.M.; de Castro, R.D.; Fernandez, L.G. Metabolite profiling, antioxidant and antibacterial activities of Brazilian propolis: Use of correlation and multivariate analyses to identify potential bioactive compounds. *Res. Food. Int.* 2018, 76, 449–457. [CrossRef]
212. Marques Pereira, A.F.; Albano, M.; Bégamo Alves, F.C.; Murbach Teles Andrade, B.F.; Furlanetto, A.; Mores Rall, V.L.; Delazari dos Santos, L.; de Oliveira Orsi, R.; Fernandes Júnior, A. Influence of apitoxin and melittin from Apis mellifera bee on Staphylococcus aureus strains. *Microb. Pathog.* **2020**, *141*, 104110. [CrossRef]

213. Haktanir, I.; Masoura, M.; Mantzouridou, F.T.; Gkatzionis, K. Mechanism of antimicrobial activity of honeybee (*Apis mellifera*) venom on Gram-negative bacteria: *Escherichia coli* and *Pseudomonas* spp. *AMB Express* **2021**, *11*, 54. [CrossRef] [PubMed]

214. Lamas, A.; Arteaga, V.; Regal, P.; Vázquez, B.; Miranda, J.M.; Cepeda, A.; Franco, C.M. Antimicrobial Activity of Five Apitoxins from *Apis mellifera* on Two Foodborne Pathogens. *Antibiotics* **2020**, *9*, 367. [CrossRef]

215. Sunyoto, T.; Verdonck, K.; El Sati, S.; Potet, J.; Picado, A.; Boelnaert, M. Uncharted territory of the epidemiological burden of cutaneous leishmaniasis in sub-Saharan Africa—A systematic review. *PLoS Negl. Trop. Dis.* **2018**, *12*, e006914. [CrossRef]

216. Bristy, T.A.; Barua, N.; Tareq, A.M.; Sakib, S.A.; Etu, S.T.; Chowdhury, K.H.; Jyoti, M.A.; Aziz, M.A.I.; Reza, A.S.M.A.; Caiazzo, E.; et al. Deciphering the pharmacological properties of methanol extract of *Psychotria calocarpa* leaves by in vivo, in vitro and in silico approaches. *Pharmaceuticals* **2020**, *13*, 183. [CrossRef]

217. Tzani, M.; Barrasa, A.; Vakali, A.; Georgakopoulou, T.; Mellou, K.; Pervanidou, D. Surveillance data for human leishmaniasis indicate the need for a sustainable action plan for its management and control, Greece, 2004 to 2018. *Eurroservoir Disease* **2021**, *26*, 2000159. [CrossRef]

218. Sundar, S.; Chakravarty, J. Leishmaniasis: An update of current pharmacotherapy. *Expert Opin. Pharmacother.* **2013**, *14*, 53–63. [CrossRef] [PubMed]

219. Sangshetti, J.N.; Khan, F.A.K.; Kulkarni, A.A.; Arote, R.; Patil, R.H.; Alvar, J.; Arana, B. Leishmaniasis, Impact and Therapeutic Needs. In *Therapeutic Understanding of Brazilian Propolis: A Meta-Analytical Approach.* *Pharmacogn. Rev.* Taub., 2015, pp. 176–183. [CrossRef]

220. Cauich-Kumul, R.; Campos, M.R.S. Bee Propolis: Properties, Chemical Composition, Applications, and Potential Health Effects. In *Bioactive Compounds*; Elsevier: Amsterdam, The Netherlands, 2019; pp. 227–243. [CrossRef]

221. El-Guendouz, S.; Lyoussi, B.; Miguel, M.G. Insight on propolis from Mediterranean countries: Chemical composition, biological activities and application fields. *Chem. Biodivers.* **2019**, *16*, e1900094. [CrossRef]

222. Siheri, W.; Zhang, T.; Ebiloma, G.U.; Biddau, M.; Woods, N.; Hussain, M.Y.; Clements, C.J.; Fearnley, J.; Ebel, R.E.; Paget, T. Chemical and antimicrobial drug discovery: Comprehensive review of the last 10 years. *RSC Adv.* **2015**, *5*, 32376–32415. [CrossRef]

223. Alvar, J.; Arana, B. Leishmaniasis, Impact and Therapeutic Needs. In *Drug Discovery for Leishmaniasis*; Rivas, L., Gil, C., Eds.; Royal Society of Chemistry: London, UK, 2017.

224. Cauich-Kumul, R.; Campos, M.R.S. Bee Propolis: Properties, Chemical Composition, Applications, and Potential Health Effects. In *Bioactive Compounds*; Elsevier: Amsterdam, The Netherlands, 2019; pp. 227–243. [CrossRef]

225. Alotaibi, A.; Ebiloma, G.U.; Williams, R.; Alenezi, S.; Donachie, A.-M.; Guillaume, S.; Igoli, J.O.; Fearnley, J.; De Koning, H.P.; Watson, D.G. European propolis is highly active against trypanosomatids including *Crithidia fasciculata*. *Sci. Rep.* **2019**, *9*, 1–10. [CrossRef]

226. Tareq, A.M.; Sohel, M.; Uddin, M.; Mahmud, M.H.; Hoque, M.; Reza, A.A.; Nasrin, M.S.; Kader, F.B.; Emran, T.B. Possible neuropharmacological effects of *Apis cerana indica* bee honey in the Swiss Albino mice. *J. Adv. Biotechnol. Exp. Ther.* **2020**, *3*, 128–134. [CrossRef]

227. da Silveira Regueira-Neto, M.; Tintino, S.R.; Rolón, M.; Coronel, C.; Vega, M.C.; de Queiroz Balbino, V.; de Melo Coutinho, H.D. Antitrypanosomal, antileishmanial and cytotoxic activities of Brazilian red propolis and plant resin of *Dalbergia ecastaphyllum* (L) Taub. *Food Chem. Toxicol.* **2018**, *119*, 215–221. [CrossRef]

228. Silici, S.; Kutluca, S. Chemical composition and antibacterial activity of propolis collected by three different races of honeybees in the same region. *J. Ethnopharmacol.* **2005**, *99*, 69–73. [CrossRef]

229. Silva, M.P.; Silva, T.M.; Mengarda, A.C.; Salvadori, M.C.; Teixeira, F.S.; Alencar, S.M.; Luz Filho, G.C.; Bueno-Silva, B.; de Moraes, P.R.T.; Branco, D.; Maia, H.N.; Santos, M.R.; Camara, C.A.; dos Santos, S.A.; dos Santos, F.d.A.R.; de Santana Filho, P.C.; Dorneles, G.P.; Romão, P.R.T.; Silva, T.M.S. Chemical Composition of Bee Pollen and Leishmanicidal Activity of Rhus flavone. *Rev. Bras. De Farmacogn.* **2021**, *31*, 176–183. [CrossRef]
Antibiotics 2021, 10, 822

235. Cuesta-Rubio, O.; Fernández, M.C.; Hernández, I.M.; Jaramillo, C.G.J.; González, V.H.; Porto, R.M.D.O.; Delangle, D.M.; Fidalgo, L.M.; Piccinelli, A.L.; Campone, L. Chemical profile and anti-leishmanial activity of three Ecuadorian propolis samples from Quito, Guayaquil and Cotacachi regions. *Fitoterapia* 2017, 120, 177–183. [CrossRef]

236. Cunha, B.C.; De Miranda, M.B.; Afonso, L.C.C.; Abreu, S.R.L.; Da Silva, G.R.; Testasica, M.C.S.; Moura, S.A.L. Brazilian green propolis hydroalcoholic extract as a therapeutic adjuvant to treat cutaneous leishmaniasis. *J. Appl. Pharm. Sci.* 2020, 10, 124–132.

237. Emran, T.B.; Mowla, T.-E.; Ahmed, S.; Zahan, S.; Rakib, A.; Hasan, M.S.; Amin, M.N.; Mow, T.R.; Uddin, M.M.N. Sedative, anxiolytic, anti-inflammatory and antipyretic effects of a chlorofuran extract from the leaves of *Urena littoralis* (Bors) L. in rodents. *J. Appl. Life Sci. Int.* 2018, 16, 1–19. [CrossRef]

238. de Miranda, M.B.; Lanna, M.F.; Nascimento, A.L.B.; de Paula, C.A.; de Souza, M.E.; Felipietto, M.; da Silva Barcelos, L.; de Moura, S.A.L. Hydroalcoholic extract of Brazilian green propolis modulates inflammatory process in mice submitted to a low protein diet. *Biomed. Pharmacother.* 2019, 109, 610–620. [CrossRef] [PubMed]

239. dos Santos Thomazelli, A.P.F.; Tomioto-Pellissier, F.; da Silva, S.S.; Panis, C.; Orsini, T.M.; Cataneo, A.H.D.; Miranda-Sapla, M.M.; Custódio, L.A.; Tatakhiara, V.L.H.; Bordignon, J. Brazilian propolis promotes immunomodulation on human cells from American Tegmentar Leishmaniasis patients and healthy donors infected with *L. braziliensis*. *Cell. Immunol.* 2017, 311, 22–27. [CrossRef]

240. Yesmin, S.; Paul, A.; Naz, T.; Rahman, A.B.M.A.; Akhter, S.F.; Wahed, M.I.I.; Emran, T.B.; Siddiqui, S.A. Membrane stabilization as a mechanism of the anti-inflammatory activity of ethanolic root extract of *Choi* (*Piper chaba*). *Clin. Phytosci.* 2020, 6, 59. [CrossRef]

241. Hegazi, A.G.; Al Guthami, F.M.; Al Gethami, A.F. Beneficial Effects of *Schistosoma mansoni* infected mice. *J. Parasit. Dis.* 2016, 40, 390–400. [CrossRef]

242. Menna-Barreto, R.F.S.; Salomo, K.; Dantas, A.P.; Santa-Rita, R.M.; Soares, M.J.; Barbosa, H.S.; de Castro, S.L. Different cell death pathways induced by drugs in *Trypanosoma cruzi*. *Microcon 2009*, 40, 157–168. [CrossRef]

243. Araujo, J.M.E.; Mendonça-Melo, L.S.; Araujo, E.D.; Fernandes, R.P.M.; Scher, R. Phenolic composition and leishmanicidal activity of red propolis and *Dalbergia ecastaphyllum* (L.) Taub (Fabaceae) Extracts from Sergipe, Brazil. *Braz. Arch. Biol. Technol. 2018*, 61. [CrossRef]

244. Arruda, C.; Ribeiro, V.P.; Mejia, J.A.A.; Almeida, M.O.; Goulart, M.O.; Candido, A.C.B.B.; dos Santos, R.A.; Magalhães, L.G.; Martins, C.H.G.; Bastos, J.K. Green propolis: Cytotoxic and leishmanicidal activities of artepillin C, p-coumaric acid, and their degradation products. *Rev. Bras. De Farmacogn.* 2020, 30, 169. [CrossRef]

245. Mohamed, A.H.; El-Nabi, S.E.; Bayomi, A.E.; Abdelaal, A.A. Effect of bee venom or propolis on molecular and parasitological aspects of *Schistosoma mansoni* infected mice. *J. Parasit. Dis.* 2016, 40, 209–220. [CrossRef]

246. Hassan, S.E.; Abou-El-Dobal, S.K.; Hegazi, A.G. Bioassay of Egyptian propolis on *Toxocara vitulorum* adult worms. *World Appl. Sci. J.* 2016, 34, 283–289.

247. Mokhtar, A.B.; El-Gayar, E.K.; Habib, E.S. In vitro anti-protozoal activity of propolis extract and cysteine proteases inhibitor (phenyl vinyl sulfone) on Blastocystis species. *J. Egypt. Soc. Parasitol.* 2016, 46, 261–272. [CrossRef] [PubMed]

248. Soufy, H.; Nadia, M.; Nasr, S.M.; Abd El-Aziz, T.H.; Khalil, F.A.M.; Ahmed, Y.F.; Abou Zeina, H.A.A. Effect of Egyptian propolis medicinal extracts versus metronidazole in a mechanism of the anti-inflammatory activity of ethanolic root extract of *Choi* (*Piper chaba*). *Clin. Phytosci.* 2020, 6, 59. [CrossRef]

249. Hegazi, A.G.; Al Guthami, F.M.; Al Gethami, A.F.; El Fadaly, H.A. Beneficial Effects of *Schistosoma mansoni* infected mice. *J. Parasit. Dis.* 2016, 40, 390–400. [CrossRef]

250. Hassan, S.E.; Abou-El-Dobal, S.K.; Hegazi, A.G. Bioassay of Egyptian propolis on *Toxocara vitulorum* adult worms. *World Appl. Sci. J.* 2016, 34, 283–289.

251. Alanzi, S.; Alenzi, N.; Alenzi, F.; Tabassum, H.; Watson, D. Chemical characterization of Saudi propolis and its antiparasitic and anticancer properties. *Sci. Rep. 2021*, 11, 9–20. [CrossRef]

252. Afroz, H.; Zakeri, S.; Mehrizi, A.A.; Molasalehi, S.; Tahghighi, A.; Shokrgozar, M.A.; Es-Haghi, A.; Djadid, N.D. Antiplasmodial assessment of four different Iranian propolis samples. *Arch. Iran. Med.* 2017, 20, 270–281.

253. Tavakoli, P.; Shaddel, M.; Yakhchali, M.; Raoufi, N.; Shamsi, H.; Dastgheib, M. Antileishmanial effects of propolis against *Leishmania major* in vitro and in vivo. *Ann. Mil. Health Sci. Res.* 2020, 18, e100630. [CrossRef]

254. Daghbar, N.; Mezioug, D.; Zahan, S.; Rakib, A.; Hasan, M.S.; Amin, M.N.; Mow, T.R.; Uddin, M.M.N. Sedative, anxiolytic, anti-inflammatory and antipyretic effects of a chloroform extract from the leaves of *Urena littoralis* (Bors) L. in rodents. *J. Appl. Life Sci. Int.* 2018, 16, 1–19. [CrossRef]

255. Marín, S.; Vlasceanu, G.M.; Tiplea, R.E.; Bucur, I.R.; Lemnaru, M.; Marín, M.M.; Grumezescu, A.M. Applications and toxicity of silver nanoparticles: A recent review. *Curr Top. Med. Chem* 2015, 15, 1596–1604. [CrossRef]
259. Al-Yousef, H.M.; Amina, M.; Alqahtani, A.S.; Alqahtani, M.S.; Malik, A.; Hatshan, M.R.; Siddiqui, M.R.H.; Khan, M.; Shaik, M.R.; Ola, M.S.; et al. Pollen Bee Aqueous Extract-Based Synthesis of Silver Nanoparticles and Evaluation of Their Anti-Cancer and Anti-Bacterial Activities. *Processes* 2020, 8, 524. [CrossRef]

260. El-Guendouz, S.; Lyoussi, B.; Lourenço, J.P.; Rosa da Costa, A.M.; Miguel, M.G.; Barrocas Dias, C.; Manhita, A.; Jordao, L.; Nogueira, I.; Faleiro, M.M. Magnetite nanoparticles functionalized with propolis against methicillin resistant strains of *Staphylococcus aureus*. *J. Taiwan Inst. Chem. Eng.* 2019, 102, 25–33. [CrossRef]

261. Chen, X.; Liu, B.; Li, X.; An, T.T.; Zhou, Y.; Li, G.; Wu-Smart, J.; Alvarez, S.; Naldrett, M.J.; Eudy, J.; et al. Identification of anti-inflammatory vesicle-like nanoparticles in honey. *J. Extracell Vesicles* 2021, 10, e12069. [CrossRef] [PubMed]

262. Iadnut, A.; Mamoon, K.; Thammasit, P.; Pawichai, S.; Tima, S.; Preechasuth, K.; Kaewkod, T.; Tragoolpua, Y.; Tragoolpua, K. In Vitro Antifungal and Antivirulence Activities of Biologically Synthesized Ethanolic Extract of Propolis-Loaded PLGA Nanoparticles against *Candida albicans*. *Evid. Based Complement. Altern. Med.* 2019, 2019, 3715481. [CrossRef] [PubMed]

263. do Nascimento, T.G.; da Silva, P.F.; Azevedo, L.F.; da Rocha, L.G.; de Moraes Porto, I.C.; Lima, E.M.T.F.; Basilio-Júnior, I.D.; Grillo, L.A.; Dornelas, C.B.; Fonseca, E.J.; et al. Polymeric Nanoparticles of Brazilian Red Propolis Extract: Preparation, Characterization, Antioxidant and Leishmanicidal Activity. *Nanoscale Res. Lett.* 2016, 11, 301. [CrossRef]

264. Saber, A.E.S.; Abdelwahab, A.K.; Amir, A.M.E.; Nassar, M.I.; Zohdi, H.F. Bee venom loaded chitosan nanoparticles as treatment for amoebiasis in mice. *J. Egypt. Soc. Parasitol.* 2017, 47, 443–458. [CrossRef]